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ABSTRACT 
The processes involved in neuroprotection and brain repair are an 
important aspect of the preservation and restoration of neuronal functions 
affected by pathological lesions. Mechanisms that stimulate, manage and 
regulate these processes thus hold potential for the development of 
treatment strategies for Alzheimer disease (AD). The aim of this thesis was 
to increase our understanding of the stimulation of neuroprotective and 
regenerative mechanisms, in particular with respect to amyloid-β (Aβ) 
accumulation and other pathological processes associated with AD. 
Mounting evidence suggests that the continuous loss of 
cholinergic neurons and nicotinic receptors (nAChRs) in the hippocampus 
and cerebral cortex could be mediated through an interaction between α7 
nAChRs and Aβ species. In paper I, we investigated interaction of α7 
nAChRs with different forms of Aβ, and the functional consequences of 
these interactions. We found that α7 nAChRs play an important role in 
mediating neuroprotective actions against Aβ-induced neurotoxicity, and 
that the assembly form of Aβ is important for the interaction with α7 
nAChRs and the downstream effects in neuronal cells. Fibrillar Aβ appears 
to cause cytotoxic effects by blocking α7 nAChRs, whereas oligomeric Aβ 
seems to activate α7 nAChRs to modulate calcium-dependent synaptic 
function.  
In paper II, we characterized the neuroprotective and 
neurotrophic actions of amyloid-modulatory candidate drugs (–)- and (+)-
phenserine and its primary metabolites, and investigated the primary 
signaling pathways responsible for mediating these effects. (+)-Phenserine 
increased the proliferation of mouse neural progenitor cells in culture via 
activation of MAPK signaling pathways, including elevated cortical levels 
of brain-derived neurotrophic factor in mouse brain. In paper III, we 
investigated the modulating effects of (+)-phenserine on the changes in 
brain synaptic function, hippocampal neurogenesis, and inflammatory cells 
at different stages of amyloid pathology. (+)-Phenserine increased 
proliferation of neural progenitor cells, and increased the maturation of 
newborn neurons in the hippocampi of young adult Tg2576 mice but not in 
older mice with advanced Aβ plaque pathology.  
In paper IV, we investigated the effects of stem cell 
transplantation and modulation of Aβ and α7 nAChRs on endogenous 
neurogenesis and astrocytosis, graft survival, and cognition. 
Intrahippocampi transplantation of human neural stem cells (hNSCs) 
improved spatial memory in young adult Tg2576 mice, and increased 
endogenous hippocampal neurogenesis. (+)-Phenserine increased graft 
survival but blocked the hNSC transplant-mediated increase in endogenous 
neurogenesis, indicative of interfering mechanisms of action. We found 
that α7 nAChR-expressing astrocytes accumulated along the needle track 
after transplantation, and that the numbers of these astrocytes correlated 
with the degree of endogenous hippocampal neurogenesis. Hence, we 
postulate a hitherto unexplored role for α7 nAChR-expressing astrocytes 
in neurogenesis and tissue remodeling. 
The clinical implications of stimulation of neuroprotection 
and brain repair in the course of AD are currently under investigation. 
However, it is my hope that the cumulative findings presented in this thesis 
will provide a better understanding of the possibilities and limitations of 
these therapeutic strategies that aim to change or halt the clinical 
progression of AD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SAMMANFATTNING PÅ SVENSKA 
Idag är över 35 miljoner individer i världen drabbade av demens. I takt 
med att andelen gamla i befolkningen stiger, beräknar man att antalet 
patienter kommer att fördubblas vart tjugonde år, vilket utgör ett allt större 
medicinskt, ekonomiskt och socialt problem.  
Den vanligaste demensformen är Alzheimers sjukdom (AD), som 
kännetecknas av patologiska förändringar i hjärnan i form av extracellulära 
depåer av amyloida plack av proteinet amyloid-β (Aβ) och intracellulära 
neurofibrillära nystan av tau-protein. En annan viktig konsekvens vid AD 
är en drastisk förlust av framförallt kolinerga nervceller i basala 
framhjärnan och dessa cellers projektionsområden i cortex och 
hippocampus. Denna förlust är kopplad till minnesstörningar som 
framträder i patienter under sjukdomens förlopp. Behandling med olika 
typer av kolinesterashämmare är idag den mest vanliga behandlingsformen 
och verkar genom att stimulera frisättning av signalsubstansen acetylkolin i 
kvarvarande kolinerga neuron.  
 
Idag tros Aβ aktivera olika sjukdomsprocesser, som tillsammans leder till 
försämrad signalering mellan nervceller och till nedsättning av de kognitiva 
funktionerna, som är karaktäristiska vid AD. Huvudfokus i min avhandling 
är att undersöka hur vi kan stimulera skyddande, (neuroprotektiva) och 
återuppbyggande (regenerativa) processer i hjärnan, med implikation för 
utvecklingen av nya behandlingsstrategier vid AD. I ett translationellt 
tillvägagångssätt har jag studerat dessa processer i modellsystem med 
neuronala celler och stamceller, kombinerat med läkemedelsbehandling 
och transplantationsstudier i AD transgena möss. 
 
I studie I undersökte vi i) hur stimulering av α7 nikotinreceptorer, som är 
viktiga för minne och inlärning, verkar skyddande mot Aβ-medierad 
toxicitet, samt ii) hur olika former av Aβ interagerar med 
nikotinreceptorer. Aggregationsformen av Aβ visade sig ha stor betydelse 
för interaktionen, där mindre och lösliga, oligomera former binder till α7 
nikotinreceptorer för att modulera synaptisk aktivitet, medan de stora, 
fibrillära formerna, tycks blockera dessa nikotinreceptorer för att orsaka 
neurotoxicitet.  
 
Studie II syftade till att karaktärisera neuroprotektiva och regenerativa, 
samt neurotrofiska egenskaper hos den Aβ-sänkande 
läkemedelskandidaten fenserin och dess metaboliter, samt att undersöka 
vilka mekanismer som medierar dessa effekter. Substanserna uppvisade 
neurotrofiska såväl som neuroprotektiva effekter i olika cellulära 
modellsystem, som delvis var medierade via proteinkinas C och MAPK-
signalering. Potentiell translationell relevans av fynden undersöktes med 
hjälp av 4-6 månader gamla Tg2576 transgena möss där fenserin ökade 
uttrycket av en neurogenes-markören doublecortin, samt ökade nivåer av 
den neurotrofiska faktorn BDNF. 
 
Fortsättningsvis utvärderade vi i studie III hur en sänkning av Aβ nivåer 
påverkar neurotrofiska och patologiska processer i hjärnan, samt när under 
sjukdomsförloppet det är möjligt att stimulera regenerativa effekter. 
Studien visar att fenserin sänker nivåer av de vanligaste amyloidformerna 
Aβ1-40 och Aβ1-42 i 4-6 och 15-18 månader gamla Tg2576 transgena 
möss. Behandlingen gav även en ökad cellproliferation i hippocampus hos 
såväl unga som äldre djur, och en ökad förgrening av nybildade neuron i 
hippocampus hos de unga djuren, men inte hos de ändre djuren med 
framträdande amyloid-patologi.  
 
Baserat på fynden i de tidigare studierna, ville vi i studie IV undersöka 
hur regenerativa processer och minnesfunktioner kan stimuleras in vivo, 
genom att kombinera transplantation av humana stamceller och 
farmakologisk behandling med läkemedel som angriper 
amyloidproduktion och stimulerar α7 nikotinreceptorer i Tg2576 
transgena möss. Stamcellstransplantation orsakade en minnesförbättring 
hos mössen, som var associerat till en ökad nybildning av nerveller 
(neurogenes) i hippocampus. Samtidig behandling med fenserin ökade 
överlevnaden av transplanterade celler men motverkade de stamcells-
medierade effekterna på kognition och neurogenes. Fynden indikerar att 
fenserin verkar antagonistiskt istället för additivt via liknande neurotrofiska 
mekanismer som de transplanterade stamcellerna. 
Kombinationsbehandling med α7 nikotinagonisten JN403 visade att det 
föreligger ett samband mellan antalet α7 nikotinreceptoruttryckande 
astrocyter och graden av neurogenes i hippocampus. Vi postulerar att 
förekomsten av denna population av astrocyter i hippocampus kan spela en 
viktig roll vid regenerativa processer i hjärnan.    
 
Vi vet idag att ansamlingen av amyloid sker tidigt under sjukdomsförloppet 
vid AD och troligen måste vi därför introducera effektiv behandling i ett 
tidigt skede av sjukdomen. Resultaten i min avhandling visar att 
möjligheten att stimulera neuroprotektion och regeneration är möjlig vid 
en ålder där patologin ännu inte är så utbredd. Tillsammans ämnar 
studierna att hjälpa till i utvecklingen av läkemedel som skyddar mot Aβ-
inducerad toxicitet, samt att öka förståelsen för möjligheter och 
begränsningar med att stimulera neurotrofiska och regenerativa processer i 
hjärnan hos AD patienter. Den kliniska tillämpningen av studier som syftar 
till att stimulera neuroprotektion och neurogenes återstår att utreda, och 
kommer förhoppningsvis bidra till terapeutiska strategier som kan 
modulera eller bromsa det kliniska förloppet vid AD.  
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1 INTRODUCTION 
1.1 ALZHEIMER DISEASE 
More than 35 million people worldwide are currently afflicted by dementia, and this 
number is expected to double every 20 years. The prevalence of dementia increases 
dramatically with age and, as life expectancy continues to increase, the population 
above 60 years of age is expected to increase by 1.25 billion by 2050. This increase is 
equivalent to 22% of the current world population, with the most rapid increase in the 
proportion of elderly expected in China, India and Latin America (Chan et al., 2013; 
Prince et al., 2013). This expectation of a dramatic increase in dementia cases places an 
enormous burden on caregivers and relatives. The worldwide cost of dementia to 
society has been estimated as 604 billion USD, equivalent to 1% of the world’s gross 
domestic product (Wimo et al., 2013). 
Fifty to 70 % of all patients with dementia have Alzheimer disease (AD), 
which is manifested clinically by a progressive decline in cognitive function, starting 
with subtle impairments to episodic memory, moving on to alterations in language and 
changes in behavior and personality, and ending with the need for total care. The 
earliest clinical features of a heterogeneous group of cognitive disorders such as AD can 
be described as mild cognitive impairment (MCI). Some patients with MCI will go on 
to develop AD, some will develop other types of dementia, and some will remain 
cognitively stable or will revert to normal. MCI may be the result of neuronal 
degeneration, but can also be caused by depression, trauma, ischemia, metabolic 
disturbances, or other conditions (Petersen et al., 2009; Winblad et al., 2004).  
The German physician Alois Alzheimer first described the pathological 
features of AD in 1906 (Alzheimer et al., 1995) and extensive research over the last two 
decades has finally provided information on the underlying pathogenesis and disease 
progression. The development of biomarkers for early diagnosis and evaluation of novel 
treatments in recent years was groundbreaking, but this branch of investigation is as yet 
in its infancy. Despite the large numbers of investigative studies and clinical trials over 
the last 30 years, the challenge to develop treatment strategies that can effectively 
prevent, halt or delay the onset and progression of AD remains.    
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1.1.1 Pathogenesis 
The characteristic histopathological features of the AD brain include extracellular 
depositions of amyloid-β (Aβ) plaques and neurofibrillary tangles (NFTs) consisting of 
hyper-phosphorylated tau. The development of Aβ and tau pathogenesis typically 
follows distinct patterns that have been classified in stages (A–C and I–VI, respectively) 
according to the brain regions affected. In stage A, amyloid progression exclusively 
involves neocortical regions, whereas in stage B, Aβ has progressed to isocortical areas 
including small amounts of Aβ deposition in the hippocampus and in some cases also in 
the entorhinal cortex. In stage C, Aβ deposits are present throughout all isocortical 
areas including the sensory and motor cortex, and subcortical regions. Progression of 
tau pathology follows a different pattern, typically progressing from the transentorhinal 
region (transentorhinal stages I–II), and spreading to the hippocampus (limbic stages 
III–IV), and then to the isocortical regions (isocortical stages V–VI) (Braak and Braak, 
1991; Braak and Braak, 1997; Thal et al., 2002).  
 
1.1.1.1 The Aβ cascade theory and beyond 
 
The amyloid casacade theory (Hardy and Higgins, 1992) postulates that accumulation 
of Aβ in the brain is a primary event that triggers other secondary pathological events, 
such as inflammatory processes, altered protein kinase signaling and oxidative stress, 
resulting in neuronal and synaptic dysfunction and eventually cell death. The 
hypothesis that Aβ is the main cause for AD pathogenesis still has strong support, 
although a growing body of evidence suggests that, because of the multifactorial nature 
of the disease, AD is unlikely to be caused solely by the accumulation of Aβ. 
Interestingly, NFTs but not Aβ plaques are associated with cognitive decline 
(Arriagada et al., 1992). Furthermore, there is a strong correlation with synaptic loss 
in AD (Terry et al., 1991). Studies indicating that AD-related genes, including familial 
AD (FAD) mutations (see section 1.1.4 Risk factors and genetics), cause synaptic 
dysfunction and neurodegeneration without the involvement of Aβ have led to the 
identification of amyloid-independent pathological pathways for the disease (Chetelat, 
2013; Pimplikar et al., 2010). Hence, the fact that both amyloid-dependent and 
amyloid-independent mechanisms contribute to AD pathology through parallel 
pathways should be taken into consideration in the development of effective treatment 
strategies, as discussed further in section 1.4 Development of treatment strategies.   
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1.1.1.2 Aβ processing and deposition  
 
The membrane-bound amyloid precursor protein (APP) can be processed along either 
the non-amyloidogenic or the amyloidogenic pathway. In the non-amyloidogenic 
pathway, APP is cleaved within the Aβ sequence by α-secretase to form soluble sAPPα 
and is then further cleaved by γ-secretase to yield a p3 fragment. Proteolytic cleavage of 
APP in the amyloidogenic pathway by β-secretase releases a soluble sAPPβ fragment, 
and subsequent cleavage by γ-secretase results in the formation of Aβ peptides. The 
most abundant Aβ peptides in the brain are 40 and 42 amino acids long; Aβ1-42 is 
more hydrophobic and prone to aggregate than the shorter Aβ fragments (De Strooper 
et al., 2010; Selkoe, 2001). It has been suggested that the shorter Aβ fragments Aβ1-14, 
Aβ1-15 and Aβ1-16 are formed via concerted cleavage by α- and β-secretase and do 
not contribute to Aβ aggregation, whereas Aβ1-17 and longer fragments are formed 
through an amyloidogenic, γ-secretase-dependent pathway (Portelius et al., 2009). Aβ 
peptides aggegate in a multistep process into various assemblies ranging from small 
oligomers to protofibrils, which later form Aβ plaques (Rochet and Lansbury, 2000) 
(figure 1). The degradation of Aβ by enzymes such as neprilysin decreases with age 
(Hellstrom-Lindahl et al., 2008), and in AD (Miners et al., 2008). 
 
 
Figure 1. Schematic outline of Aβ aggregation from monomers to plaques. 
 
One of the important goals of AD research is to elucidate which aggregated forms of 
Aβ are involved in mediating the impaired cellular functions in the brain. An increasing 
number of studies have indicated that Aβ oligomers may be the main contributors to 
cognitive decline in AD (Lambert et al., 1998; Walsh and Selkoe, 2007), and that the 
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presence of these correlates with cognitive decline better than the presence of fibrillar 
Aβ (Naslund et al., 2000). One of the main focuses of current AD research is to 
understand the actions of the various Aβ assemblies on their cellular targets. To date, 
in vitro studies have mainly used recombinant or synthetic Aβ. Isolation of Aβ species 
from AD postmortem brains is laborious, mostly because the oligomers are sensitive 
to the reagents used in experimental protocols and can be difficult to detect. The 
specificity of antibodies targeting oligomeric Aβ is another important issue. Recent 
findings suggest that Aβ dimers isolated from AD autopsied brain tissue impair 
synaptic function and are associated with Alzheimer-type dementia (Mc Donald et al., 
2010; Shankar et al., 2008). Other studies suggest that Aβ-derived diffusible ligands 
(ADDLs) (Gong et al., 2003; Lambert et al., 1998) could be important components of 
AD pathology. Characterization of Aβ assemblies in postmortem human brain tissue 
has revealed that higher molecular weight oligomers, including dodecamers (Gong et 
al., 2003), decamers and pentamers, seem to be more prevalent than others in the AD 
brain, and that pentamers are correlated with reductions in choline acetyltransferase 
(ChAT) levels in the frontal cortices of AD patients (Bao et al., 2012). Other species 
thought to play a role in AD pathogenesis are 56 kDa assemblies (referred to as 
Aβ*56) (Lesne et al., 2006), globulomers (Gellermann et al., 2008), and protofibrils 
(Harper et al., 1997; Walsh et al., 1997).  
 Aβ probably also plays a physiological role in the healthy brain. In fact, 
various Aβ oligomer assemblies have been found and characterized in the brains of 
cognitively normal control subjects (Bao et al., 2012; Lesne et al., 2013). Furthermore, 
monomeric Aβ protects rat cortical neurons against trophic deprivation and 
excitotoxicity via the phosphatidyl inositol-3 kinase (PI3K) pathway (Giuffrida et al., 
2009).  
  
1.1.1.3 Tau 
 
Tau is a microtubulin-associated protein that is abundant in neurons in the CNS, 
mainly in the neuron axons but also in the dendrites (Grundke-Iqbal et al., 1986; Ittner 
et al., 2010). Tau stabilizes the microtubule structure of the neuron and regulates 
axonal transport (Ittner and Gotz, 2011). When tau is hyperphosphorylated, it 
dissociates from the microtubules and assembles into paired filaments, which then 
aggregate to form NFTs. Dissociation from the microtubules results in changes to the 
axonal transport system, and subsequent synaptic loss (Iqbal and Grundke-Iqbal, 2005). 
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Synaptic dysfunction and neuronal degeneration parallel the formation of NFTs, but 
the causal link between these events is as yet unclear (Serrano-Pozo et al., 2011).  
 
1.1.1.4 Inflammatory changes 
 
The classical neuropathological features, Aβ plaques and NFTs, are accompanied by 
hallmark increases in activated microglia and reactive astrocytes in the brains of AD 
patients (Beach et al., 1989; Itagaki et al., 1989; Masliah et al., 1991). The 
inflammatory responses could have a beneficial function; glial cells clear Aβ and 
debris through phagocytic mechanisms and play an important role in tissue repair 
and remodeling. However, uncontrolled inflammation with excess production of 
neurotoxic species can further potentiate pathological processes in AD (Glass et al., 
2010). Recent data suggest that microglia and astrocytes play important roles in 
regulating and maintaining neuronal activity, which can be adversely influenced by 
elevated Aβ levels (Graeber, 2010). Aβ in turn increases the synthesis of microglia and 
reactive astrocytes, and the release of pro-inflammatory cytokines such as interleukin-
1β (IL-1β) and tumor necrosis factor-α (TNFα), and chemokines such as monocyte 
chemo-attractant protein-1 (MCP-1) (Combs et al., 2001; Lindberg et al., 2005; Meda 
et al., 1995). MCP-1 also contributes to the recruitment of astrocytes around Aβ 
plaques (Wyss-Coray et al., 2003). Aβ-mediated activation of microglia stimulates the 
production of reactive oxygen species, which in turn leads to oxidative stress and 
mitochondrial dysfunction (Baloyannis et al., 2004; Butterfield et al., 2001; Sas et al., 
2007). The increased production of cytokines and reactive oxygen species results in 
targeting of cholinergic neurons and activation of astrocytes, which further amplifies 
the inflammatory signals (Glass et al., 2010). Whether inflammation in AD is a cause 
or consequence of the disease, is as yet unknown.  
 
1.1.2 The cholinergic system and nicotinic receptors in AD 
The cholinergic innervation system in the brain consists of basal forebrain cholinergic 
neurons that project to the hippocampus, amygdala, and cerebral cortex. Cholinergic 
neurotransmission is mediated by the release of acetylcholine (ACh), which is 
synthesized by ChAT and upon release interacts with neuronal nicotinic and 
muscarinic ACh receptors (nAChRs and mAChRs, respectively). ACh is inactivated 
through hydrolysis by acetylcholinesterase (AChE) in the synaptic cleft (Paterson and 
Nordberg, 2000; Schliebs and Arendt, 2006).  
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The nAChRs play an important role in regulating cognitive functions such as 
learning, memory and attention. They are located pre- and postsynaptically, as well as 
peri- and extra-synaptically, and modulate the release not only of ACh but also of other 
neurotransmitters such as dopamine, noradrenaline, serotonin, γ-aminobutyric acid 
(GABA), and glutamate (Paterson and Nordberg, 2000; Wonnacott, 1997). The 
nAChRs are ion channels composed of either α subunits (α2-10) or a combination of α 
and β subunits (β2-4). These combinations give rise to receptors with distinct 
physiological and pharmacological properties. The most common nAChR subunits in 
the mammalian brain are α3, α4, α7 and β2 (Gotti and Clementi, 2004; Paterson and 
Nordberg, 2000). This thesis focuses mainly on the α7 nAChRs, which are expressed 
throughout the human brain with the highest levels in the hippocampus, caudate 
nucleus, thalamic nuclei, geniculate bodies, diagonal band of broca and nucleus basalis 
of meynert (Paterson and Nordberg, 2000; Rubboli et al., 1994). 
Although several other neurotransmitter systems are affected in AD, the 
reduction in synthesis of ACh (the so-called cholinergic deficit) is the most severe effect 
and this correlates well with cognitive decline (Kadir et al., 2006; Nordberg et al., 
1995). Progressive degeneration of cholinergic neurons occurs in AD, accompanied by 
reductions in the levels of ChAT (Davies and Maloney, 1976; Perry et al., 1977) and 
also in nAChRs, mostly affecting levels of neuronal α3, α4 and α7 nAChR subunits in 
the brain (Nordberg, 2001; Paterson and Nordberg, 2000). Although one study showed 
that levels of α4β2 nAChRs had already been reduced by the time the MCI stage was 
reached (Kendziorra et al., 2011), another found that, when measured using 
[3H]epibatidine binding, the loss in nAChRs occurred after the transition from MCI to 
AD (Sabbagh et al., 2006). Interestingly, the number of α7 nAChRs is reduced on 
neurons but is up-regulated on astrocytes surrounding Aβ plaques in AD postmortem 
brains (Yu et al., 2005). Regional distribution of mRNA levels for α3 and α4 nAChRs 
are not altered, whereas mRNA levels for α7 nAChRs are elevated in the hippocampi 
of AD patients (Hellstrom-Lindahl et al., 1999). These findings suggest that the altered 
nAChR levels in AD occur mainly after transcription. 
 
1.1.3 Amyloid-β interactions with nicotinic receptors  
It is possible that Aβ-mediated neurotoxicity is the result of an interaction between Aβ 
and nAChRs in the brain; Aβ has been shown to interact with nAChRs on neurons 
with resultant impairment of synaptic function (Pettit et al., 2001; Wang et al., 2000a; 
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Wang et al., 2000b). One suggested mechanism is that Aβ/α7 nAChR complexes on 
glutaminergic neurons are internalized and then contribute to intracellular 
accumulation of Aβ, endocytosis of N-methyl-D-aspartate (NMDA) receptors, and 
impaired synaptic function (Snyder et al., 2005). In support of this, increased 
accumulations of Aβ have been found in cholinergic neurons with high expression of 
α7 nAChRs in the AD brain (Nagele et al., 2002), which could cause these neurons to 
be particularly vulnerable in AD (D'Andrea and Nagele, 2006). Several studies have 
indicated that nAChRs might be involved in promoting neuroprotective mechanisms in 
the brain (Buckingham et al., 2009; Kihara et al., 1997; Liu and Zhao, 2004; Picciotto 
and Zoli, 2008), which has led to an interest in developing drugs that activate nAChRs. 
Several workers have shown that nAChR agonists protect neurons against Aβ-induced 
toxicity (Kihara et al., 1997; Liu and Zhao, 2004). Both α4β2 and α7 nAchRs have 
been implicated in neuroprotection against Aβ-induced toxicity (Kihara et al., 1998; 
Takada et al., 2003), although α7 nAChRs are considered the primary mediator.  
A number of mechanistic explanations for these effects have been proposed. A 
study that tested the neuroprotective effects of various nicotinic agonists showed that the 
extent of protection was associated with the extent of upregulation of α7 nAChRs 
(Jonnala and Buccafusco, 2001), suggesting that this type of positive feedback loop 
could be important in potentiating the neuroprotective effect. But what downstream 
signalling pathways are involved in nAChR-mediated neuroprotection? The well 
known anti-apoptotic PI3K/v-akt murine thymoma viral oncogene homolog (PI3K-
AKT) pathway has been identified as an important component, possibly through the 
up-regulation of the anti-apoptotic protein BCL 2 (Arias et al., 2004). The Janus kinase-
2/signal transducer and activator of transcription-3 (JAK/STAT) pathway is also 
activated through stimulation of α7 nAChRs, where JAK may link the PI3K pathway 
with the neuroprotective STAT signaling pathway (Shaw et al., 2002). However, it is 
not known whether this pathway is essential for neuroprotection. Another pathway 
that has been identified as an important mediator of α7 nAChR-induced 
neuroprotection, is the mitogen-activated protein kinase (MAPK)/ERK pathway. α7 
nAChR agonists have been shown to promote neuronal survival via activation of 
ERK1/2, which is upstream of the transcription factor c-Myc (which provides anti-
apoptotic effects) and the cAMP response element-binding protein (CREB; which is 
important for a variety of functions, including memory formation) (Bitner et al., 2007; 
Dajas-Bailador et al., 2002b; Ren et al., 2005). The α7 nAChR-mediated increase in 
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intracellular levels of calcium ions, both via the receptor but also through the activation 
of intracellular stores, is also thought to be important for neuroprotection (Dajas-
Bailador et al., 2002a; Ren et al., 2005)  
Paradoxically, Aβ also activates signalling pathways such as MAPK-CREB 
mentioned above, and studies have indicated that the concentrations and time course of 
Aβ exposure determine which pathways are activated (Bell et al., 2004; Dineley et al., 
2001). This suggests that it might be possible to pharmacologically intervene in 
downstream processes to shift the actions of Aβ towards a pro-survival route.    
In addition to their association with neuroprotection, a recent study reported 
that α7 nAChRs also play an important role in the integration and maturation of 
newborn hippocampal neurons (Campbell et al., 2010). These findings suggest that α7 
nAChRs are important in mediating both neuroprotective and neurotrophic effects.   
 
1.1.4 Risk factors and genetics 
Several risk factors are considered to be important in the etiology of AD (Reitz et al., 
2011). Advancing age is the greatest risk factor but lower levels of formal education 
have also been implicated (Stern, 2012; Stern et al., 1994), possibly as a result of a 
smaller cognitive reserve as compensation for increasing pathological changes in the brain. 
The term cognitive reserve, which has emerged from epidemiological studies, is 
associated with the theory that the brain possesses an intrinsic ability to cope with 
pathology through cognitive processing and compensatory mechanisms, which can help 
to delay the cognitive decline in AD (Stern, 2012). The level of cognitive and social 
engagement could also be important for brain function and the risk of dementia 
(Fratiglioni et al., 2004). Many risk factors for cardiovascular diseases have also been 
shown to increase the risk of developing AD and other dementias. These riskfactors 
include high blood glucose and diabetes mellitus (Ahtiluoto et al., 2010), hypertension, 
obesity in midlife, and high cholesterol levels (Kivipelto et al., 2005). Traumatic brain 
injury is another important factor which can increase the risk of AD by a factor of 
approximately 4.5 (Plassman et al., 2000). 
 Alzheimer’s disease can be classified as sporadic or hereditary (FAD), the latter 
representing 5-10% of all diagnosed AD cases. Early and late onset AD are 
differentiated depending on when the first symptoms appear: before or after the age of 
65 years. To date, genetic studies have revealed nearly 260 mutations 
(http://www.molgen.ua.ac.be/ADMutations/) in three genes associated with familial 
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autosomal-dominant AD: APP on chromosome 21, including the Swedish double 
mutation 670/671, and the genes encoding the two presenilin (PS) proteins that are 
components of the γ-secretase complex, PSEN1 on chromosome 14 and PSEN2 on 
chromosome 1 (Bertram and Tanzi, 2008; Mullan et al., 1992; St George-Hyslop, 
2000). Generally, these mutations give rise to increased production of Aβ. Mutations 
such as the Swedish mutation that are situated close to the β-secretase cleavage site on 
the APP gene result in increased production of both Aβ1-40 and Aβ1-42 (Citron et al., 
1992). Mutations close to the γ-secretase cleavage site on the APP gene and those on 
the PSEN genes selectively increase the formation of Aβ1-42 (Goate et al., 1991; 
Kumar-Singh et al., 2006). A recent study of AD patients with the arctic APP mutation 
showed low levels of fibrillar Aβ in the brain but pathological levels of Aβ and tau in the 
cerebrospinal fluid (CSF) (Scholl et al., 2012), indicative of oligomeric rather than 
fibrillar Aβ in the brains of these patients. Several other susceptible genes have also 
been identified as risk factors for AD. The most common of these, ApoE, encodes for 
apolipoprotein E, which is involved in cholesterol transport and metabolism and exists 
in the three isoforms ε2, ε3, and ε4. The ε4 allele is known to increase the risk of AD 
and to result in earlier onset of the disease. The risk is increased three-fold in ε4 
heterozygotes and 15-fold in homozygotes (Ashford, 2004).  
 In contrast to most other mutations, a rare gene variant with a mutation close 
to the β-secretase cleaving site on the APP gene lowers the production of Aβ and is 
neuroprotective. Individuals with this mutation perform better than control subjects in 
cognitive tests, which raises interesting questions on whether the improved cognition is 
linked to the Aβ effects (Jonsson et al., 2012).  
 
 
1.2 TRANSGENIC MOUSE MODELS OF AD 
Several transgenic mouse models expressing human FAD mutations have been 
developed; these are used as in vivo model systems in research to study the pathological 
processes of AD and to test the effects of potential therapeutic interventions (Ashe and 
Zahs, 2010; Hall and Roberson, 2012; Philipson et al., 2010). Although these mouse 
models have provided critical knowledge regarding the mechanisms of AD, they do not 
capture its complete pathogenesis. Because of differences between mouse strains (Table 
1) and between experimental animals and AD patients, findings from these mice have 
to be interpreted with caution. Transgenic mice harboring mutations in genes coding 
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for APP, PS1 and tau (referred to as 3xTg-AD) exhibit Aβ pathology, NFTs and 
impaired synaptic plasticity, mirroring AD pathology to a large extent (Oddo et al., 
2003a; Oddo et al., 2003b). New transgenic rodent models, such as the transgenic rat 
TgF344-A, which develops amyloid pathology, NFTs, and substantial neuronal loss 
(Cohen et al., 2013), are also under development.  
 
Table 1. Main features and characteristics of commonly used transgenic mouse 
models in AD research. 
Strain FAD mutation Neuropathology Behaviour Reference 
Tg2576 
(APPswe) 
APP695 
(K670N/M671L) 
Aβ deposition at 9 
months, no 
neuronal loss but 
reduced spine 
density  
Spatial 
learning 
deficits at  
5–6 months 
(Hsiao et al., 
1996; Lesne et al., 
2006; Perez-Cruz 
et al., 2011; 
Stewart et al., 
2011) 
APP23 APP571 
(K670N/M671L) 
Aβ deposition at 6 
months, some 
neuronal loss 
Impairment 
in passive 
avoidance 
tests, spatial 
memory. 
(Calhoun et al., 
1998; Lalonde et 
al., 2002; 
Sturchler-Pierrat 
et al., 1997) 
APP/PS1 APP571 
(K670N/M671L, 
PS1 (A246E) 
Aβ deposition at 3–
4 months, minor 
neuronal loss 
Cognitive 
impairment 
at 4 months 
(Borchelt et al., 
1997; Holcomb et 
al., 1998) 
 
3xTg-AD APP695 
(K670N/M671L,
PS1(M146V), tau 
(P301L) 
Aβ deposition at 6 
months, NFTs at 15 
months, impaired 
synaptic plasticity 
Retention/ 
retrieval 
deficits at  
4–5 months 
(Billings et al., 
2005; Oddo et al., 
2003a; Oddo et 
al., 2003b) 
5xTg-AD APP695 
(K670N/M671L,
Florida (I716V) 
and London 
(V717I), PS1 
(M146L and 
L286V)  
Aβ deposition at 2 
months,  
neuronal loss 
Spatial 
learning 
deficits at  
4–6 months 
(Oakley et al., 
2006; Ohno, 
2009) 
 
 
1.3 NEW NEURONS IN ADULT BRAINS – A PARADIGM SHIFT 
Neural precursor cells (NPCs) in the CNS are multipotent cells that can mature into 
neurons, astrocytes or oligodendrocytes (Palmer et al., 1999; Palmer et al., 1995). 
Neurogenesis is generally defined as the generation of functional neurons from these 
precursor cells, thus including every step from cell proliferation to the integration of the 
newborn neurons into functional neural circuits. These processes were initially thought 
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to occur only during the embryonic and fetal stages of development. The first evidence 
that neurogenesis occurs postnatally in the hippocampus and in the olfactory bulb was 
demonstrated in the 1960s by injecting rodents with [3H]-thymidine to label dividing 
cells and then morphologically studying their fate (Altman and Das, 1965; Altman and 
Das, 1967; Caviness, 1973). However, newborn neurons in the adult brain were not 
proven functional until an important study in songbirds showed functional integration 
of newborn neurons in the CNS (Paton and Nottebohm, 1984). A series of papers later 
showed that newly generated neurons survived for long periods, had extending axons, 
and could receive synaptic input (Kaplan and Bell, 1983; Kaplan and Hinds, 1977; 
Stanfield and Trice, 1988). Later, hippocampal neurogenesis was also confirmed in 
adult animals (Kempermann et al., 1998; Kuhn et al., 1996). Despite the results of 
numerous studies in rodents, it was thought for a long time that neurogenesis did not 
occur in the adult human brain. New neurons in the brains of adult humans were first 
discovered through the pioneering work of Eriksson and colleagues in 1998 (Eriksson et 
al., 1998). In this study, five terminally ill patients (average age 64 years) received 
injections of the thymidine analog bromodeoxyuridine (BrdU) before death, which 
subsequently enabled postmortem analysis and the identification of neural precursors 
that had undergone neuronal differentiation in the brain (Eriksson et al., 1998). It later 
became evident that the date of cell birth could be estimated in older adult populations 
by measuring 14C levels in genomic DNA, since the levels of 14C increased after atomic 
bomb testing during the cold war (1955–1963) (Spalding et al., 2005).  
Hence, it is now well known that neurogenesis continues throughout adulthood, 
mainly in two regions of the brain: i) the subventricular zone (SVZ) lining the lateral 
ventricles, from where new neurons migrate along the rostral migratory stream to the 
olfactory bulb where they mature into interneurons, and ii) the subgranular zone (SGZ) 
of the dentate gyrus (DG) in the hippocampus, as reviewed in a number of publications 
(Gage et al., 1998; Ming and Song, 2005; Ming and Song, 2011; Suh et al., 2009). 
Neurogenesis in the DG involves multiple developmental steps, in which NPCs in the 
subgranular layer undergo cell proliferation, neuronal differentiation, migration to the 
molecular granular layer of the DG, molecular and axonal targeting of the newborn 
neuron, and functional integration into existing neuronal networks (Ehninger and 
Kempermann, 2008), as schematically illustrated in figure 2. Spalding and colleagues 
estimate that about 700 new neurons are born each day in the human hippocampus 
(Spalding et al., 2013). In contrast, neurogenesis in the olfactory bulb is sparse, or may 
not occur at all, in humans (Bergmann et al., 2012). This is not surprising, considering 
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the important role that the hippocampus plays in cognitive function in humans, while 
the olfactory bulb is less developed in humans than in rodents. 
 
 
Figure 2. Schematic illustration of hippocampal neurogenesis. 
 
1.3.1 Adult neurogenesis is regulated by a myriad of factors 
Neurogenesis is intricately regulated by a large number of intrinsic and extrinsic 
factors. Proliferating NPCs are usually found in the vicinity of the vasculature of the 
brain, where vasculature-derived neurotrophic factors such as vascular endothelial 
growth factor stimulate neurogenesis (Jin et al., 2002; Schanzer et al., 2004). 
Astrocytes in the vicinity of the neurogenic zones in the brain are known to specifically 
regulate neurogenesis (Song et al., 2002) via astrocyte-secreted factors such as Wnt3a 
(Barkho et al., 2006; Lie et al., 2005), and membrane-bound factor Ephrin-B (Ashton et 
al., 2012). Astrocytes are associated with neuronal development, neurotransmission, 
synaptic plasticity and maintenance of brain homeostasis, and a number of studies have 
shown that they provide trophic, structural, and metabolic support to neurons 
(Nedergaard and Verkhratsky, 2012; Parpura and Verkhratsky, 2012; Ullian et al., 
2004). 
Extrinsic factors such as physical activity and an enriched environment 
are also potent regulators of neurogenesis. Physical activity stimulates the proliferation 
of NPCs, neuronal maturation and synaptogenesis (Ho et al., 2009; Kempermann et 
al., 1998; Snyder et al., 2009), and an enriched environment enhances hippocampal 
neurogenesis (Brown et al., 2003; Kempermann et al., 1998).  
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1.3.2 Does neurogenesis play a significant role in brain function and memory?  
The functional relevance of adult hippocampal neurogenesis on behavioral traits and 
on learning and memory has so far mainly been studied in rodents, using 
hippocampus-dependent spatial memory tests such as the Morris water maze 
(MWM). A few studies have demonstrated a correlation between hippocampal 
neurogenesis and spatial learning and memory (Drapeau et al., 2003; Kempermann 
and Gage, 2002), but others have shown conflicting results (Gould and Tanapat, 
1999; van Praag et al., 1999), probably because of confounding factors such as 
physical activity and stress, which can also affect neurogenesis. Although research 
since the first studies by Altman and colleagues some 50 years ago has provided us with 
a vast amount of knowledge in the field of adult neurogenesis, a number of questions 
remain. Nonetheless, given the rapid development of powerful tools, markers and 
model systems, there is reason to hope that current and future research will further 
improve our molecular understanding of neurogenesis and the intrinsic mechanisms 
behind neurogenesis during life, along with the contribution of neurogenesis to 
cognitive function.  
Although postmortem studies have provided much information, non-
invasive in vivo studies carried out over time are pivotal in order to understand the 
function of neurogenesis in physiological and pathological conditions, as reviewed by 
Ho et al. (Ho et al., 2013). These in vivo techniques include brain imaging with magnetic 
resonance imaging (MRI), involving scanners which can offer close to single-cell 
resolution and the possibility of measuring cerebral blood volume and blood flow. 
Interestingly, labeling transplanted stem cells with 19F enables in vivo tracking of the graft 
by MRI (Boehm-Sturm et al., 2011). Imaging with positron emission tomography 
(PET) tracers that specifically label markers for regenerative processes in the brain is 
also a promising approach for studying neurogenesis in vivo. Nevertheless, to date no 
study has demonstrated a relationship between neurogenesis and alterations in 
hippocampal volume or function.  
 
1.3.3 Neurogenesis in AD 
The hippocampus is one of the earliest affected brain regions in AD (Braak et al., 1993). 
It is tempting to speculate that the mechanisms associated with cognitive reserve are 
also associated with increased neurogenesis, although this remains to be proven. 
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Expression of neuronal markers is increased in hippocampal regions of autopsied brains 
from AD patients (Jin et al., 2004b), suggesting that neurogenesis may be a natural 
defense strategy against neurodegeneration in AD. However, a recent study by Perry 
and colleagues showed that increased proliferation of NPCs in the hippocampus of AD 
patients does not result in increased numbers of matured neurons (Perry et al., 2012).  
 Investigations into hippocampal neurogenesis in mouse models of AD have 
provided conflicting findings. Most studies report compromised neurogenesis (Demars 
et al., 2010; Haughey et al., 2002; Zhang et al., 2007), but some have described 
increased neurogenesis (Jin et al., 2004a; Lopez-Toledano and Shelanski, 2007). 
These contradictory findings may be due to differences in the transgenic models used 
in the studies, the age of the mice, or the markers used to detect and quantify 
proliferating and differentiating NPCs.  
Brain-derived neurotrophic factor (BDNF) plays an essential role in 
neuronal development; it is involved in cell proliferation, neuronal differentiation, 
integration into neuronal circuits, and synaptic plasticity in the brain (Autry and 
Monteggia, 2012; Ming and Song, 2005; Ming and Song, 2011). In AD, levels of 
BDNF are decreased in the entorhinal cortex and the hippocampus (Connor et al., 
1997; Hock et al., 2000; Narisawa-Saito et al., 1996). Aβ oligomers impair BDNF 
axonal retrograde signalling in vitro (Poon et al., 2011), suggesting a possible mechanism 
for impaired synaptic function early in AD.  
 
 
1.4 DEVELOPMENT OF TREATMENT STRATEGIES 
A vast array of treatment strategies for AD is currently being developed or tested in 
clinical trials. These strategies include the use of anti-inflammatory drugs, antioxidants, 
serotonin receptor modulators, drugs targeting tau phosphorylation and aggregation, 
and anti-amyloid drugs (the latter is discussed further in section 1.4.3 Targeting Aβ). The 
drugs under investigation have been reviewed elsewhere (Mangialasche et al., 2010; 
Misra and Medhi, 2013) or can be seen at www.clinicaltrials.gov.  An outline of the 
various treatment strategies for AD is given in figure 3.  
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Figure 3. Outline of therapeutic strategies for AD.  
 
1.4.1 Use of brain imaging and CSF biomarkers to evaluate treatment effects over 
time 
The rapid development of molecular imaging techniques using selective radiotracers 
has provided new means of studying pathological changes and treatment effects in 
living patients. Together with development of CSF biomarkers, these techniques have 
enabled longitudinal monitoring of Aβ levels, tau levels, inflammatory changes, 
metabolic and structural alterations, and changes in neurotransmission. Recent 
assessment of various biomarkers in patients with FAD suggests that pathological 
changes in the brain start decades before the onset of cognitive symptoms (Bateman et 
al., 2012; Scholl et al., 2011). Consequently, early detection and prediction of AD could 
facilitate the evaluation of early intervention strategies. 
 The PET tracer 11C-Pittsburgh compound-B (PIB), the most widely used 
amyloid tracer, has allowed visualization of the deposition of fibrillar Aβ very early in 
the course of AD, and has also facilitated investigation of Aβ progression in living 
patients (Nordberg, 2004; Nordberg et al., 2010). High PIB retention has been observed 
in cortical brain regions in patients with AD (Klunk et al., 2004) and those with MCI 
who later converted to AD (Forsberg et al., 2008; Kemppainen et al., 2007). Astrogliosis 
can also be seen in vivo using the PET tracer 11C-deprenyl, which binds to monoamine 
oxidase type B predominantly localised to the outer mitochondria membrane of 
reactive astrocytes (Fowler et al., 2005). Recent data indicate that binding of 11C-L-
  16 
deuterodeprenyl (11C-DED) in the frontal and parietal cortices is higher in patients with 
MCI than in those with AD or control subjects (Carter et al., 2012). Furthermore, in a 
recent study in autopsied AD brain tissue, there were no correlations between 3H-
deprenyl binding and 3H-PIB binding (Kadir et al., 2011), and each of these ligands 
showed different laminar distributions in the brain (Marutle et al., 2013), suggesting that 
the time course of the inflammatory process is different from that of Aß pathology. 
Kadir et al. also found a negative correlation between fibrillar Aβ levels and the 
number of nAChRs in the AD brain, as measured with 3H-PIB and 3H-nicotine 
binding, respectively (Kadir et al., 2011), which substantiates the possibility that 
nAChRs are involved in Aβ pathology. Cell function can be assessed by measuring 
glucose consumption and metabolism in the tissue with the glucose analog 2-18F-fluoro-
2-deoxy-D-glucose (FDG). FDG PET has shown that glucose metabolism decreases in 
the posterior singulate cortices, the temporal lobe including the hippocampus, and the 
entorhinal cortex in MCI and AD patients (Mosconi, 2005). FDG PET measurement in 
FAD patients with a PSEN1 mutation suggests that aberrant glucose metabolism can be 
detected long before the onset of cognitive symptoms (Scholl et al., 2011). Furthermore, 
there is a strong association between decreased glucose consumption and cognitive 
decline (Landau et al., 2011).  
 The three most established and validated CSF biomarkers reflecting AD 
pathology are the levels of Aβ1-42, and total and phosphorylated tau. CSF Aβ1-42 
levels are decreased in AD, possibly reflecting the increase in Aβ plaques in the brain, 
whereas CSF tau levels are elevated (Hansson et al., 2006; Mattsson et al., 2009). 
 A model involving the temporal patterns of five established biomarkers in AD, 
which was developed by Jack and colleagues in 2010, has recently been updated and 
modified. A tentative, hypothetical summary of these markers in combination with 
those previously discussed is illustrated in figure 4. 
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Figure 4. Pathological changes and the tentative time course of these changes in 
biomarkers used in studies of MCI and AD (Jack et al., 2013; Kadir et al., 2010; 
Nordberg et al., 2010). 
 
1.4.2 Importance and caveats of current treatment  
Current treatment for AD consists of the AChE inhibitors (AChEIs) donepezil, 
galantamine and rivastigmine, which have been approved for mild to moderate AD, 
and the NMDA receptor antagonist memantine, which has been approved for 
moderate to severe AD. The AChEIs were designed to reduce the activity of AChE, 
and BuChE in the case of rivastigmine, and thus prolong the effect of ACh in the 
synaptic cleft, whereas memantine inhibits NMDA receptors to prevent glutamate-
mediated neurotoxicity. Improved cerebral glucose metabolism has also been observed 
in AD patients treated with rivastigmine, galantamine or donepezil (Keller et al., 2010; 
Mega et al., 2005; Stefanova et al., 2006; Teipel et al., 2006). Rivastigmine increased 
11C-nicotine binding in the brains of AD patients after 3 months' treatment, and a 
positive correlation between 11C-nicotine and cognition was found in patients treated 
with galantamine or rivastigmine for 12 months (Kadir et al., 2008b; Kadir et al., 
2007). However, despite the various positive effects that current treatment offers, there 
is an urgent need for novel, effective disease-modifying drugs.  
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1.4.3 Targeting Aβ  
Of all the AD drugs currently in clinical trials, most target aspects of Aβ pathology. 
Some target Aβ production by inhibiting β- or γ-secretases, and some prevent Aβ 
aggregation and thus the formation of amyloid plaques. γ-Secretase inhibitors are 
currently being tested in clinical trials, and some studies have reported reduced Aβ 
levels but have also reported adverse effects. It is hoped that strategies to develop 
inhibitors that are more APP-selective, with fewer effects on other γ-secretase substrates 
(De Strooper et al., 2010; Imbimbo, 2008), and further evaluation of the inhibitors 
currently under development will reveal positive effects on cognition.  
Immunization therapy that increases the removal of Aβ in the brain is also under 
evaluation. Aβ vaccines have been tested in clinical trials of AD patients since 2001. 
The first clinical trial was halted because of adverse drug reactions including 
encephalitis and increased loss of brain volume, and because no significant effects on 
cognition were observed (Fox et al., 2005; Gilman et al., 2005; Orgogozo et al., 2003). 
However, reductions in fibrillar Aβ have been reported in subsequent trials; at least 20 
Aβ vaccines are currently in clinical trials, and trials of passive immunization in 
conjunction with administration of antibodies that recognize different parts of the Aβ 
peptides are also underway (Lemere and Masliah, 2010; Mangialasche et al., 2010). In 
2010, the monoclonal antibody bapineuzumab was reported to significantly reduce 
fibrillar amyloid levels in a subgroup of patients after 78 weeks of treatment, as 
measured with PIB PET (Rinne et al., 2010). However, despite the reductions in Aβ, no 
effect on cognition was observed. Another monoclonal antibody, solanezumab, was 
recently studied in two 18-month trials. When the data from the two trials were 
combined, a trend towards a cognitive effect was shown (Gandy and DeKosky, 2013). 
Two experimental AD drugs, the AChEI (–)-phenserine, and its cholinergically inert 
enantiomer (+)-phenserine, are both APP-synthesis inhibitors and thus lower Aβ levels 
(Greig et al., 2005; Lahiri et al., 2007; Mikkilineni et al., 2012; Shaw et al., 2001). A 
clinical study of (–)-phenserine treatment in patients with mild AD showed that the 
decreased amyloid load in the brain, as measured with PIB PET, correlated with 
increased levels of Aβ1-40 in the CSF, together with improvement in cognition after 3 
months (Kadir et al., 2008a). (–)-Phenserine reached phase 3 clinical trials (Winblad et 
al., 2010), and is currently being reformulated to optimize its pharmacological actions 
(Becker and Greig, 2012). (+)-Phenserine has recently undergone phase 1 tolerability 
and target engagement trials, which reported lowered CSF levels of APP metabolites, 
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Aβ, tau and inflammatory markers in subjects with MCI (Maccecchini et al., 2012).  
 
1.4.4 In search of prevention or disease modification – What can we learn from 
recent preclinical and clinical trials in AD? 
The recent failed Aβ clinical trials in mild to moderate AD, with various drugs 
decreasing Aβ levels in the brain but showing no effects on cognitive function, suggest 
that earlier therapeutic interventions may be necessary (Selkoe, 2012). Current 
research is focusing on the development of treatments that target the underlying 
pathology and the administration of these in the early preclinical stages of AD (figure 
5). In addition, several preventive clinical studies are planned in asymptomatic 
members of families at high risk of developing AD because of a genetic predisposition 
(Aisen et al., 2013). Current thinking is that future therapy will be dependent on early 
diagnosis and the ability to identify the right time for treatment during disease 
progression. Successful treatment of AD depends heavily on future advances in the 
identification of biomarkers, including structural, pathological and functional imaging 
as well as CSF markers, for early diagnosis and evaluation of the effects of new drugs 
(Hampel et al., 2010; Nordberg, 2011).  
 To date, a large number of novel treatment strategies have been 
successful in animal models, only to fail in subsequent clinical trials. Despite the great 
disappointment associated with these failures, the trials have provided important 
information that can be used to revise future pre-clinical and clinical trials. Factors that 
critically determine the outcomes of clinical trials include the cohort size, the length of 
the trial, and the choice of endpoints. The enormous cost associated with large trials is 
certainly a limiting factor for study design. It is also valid to question whether 
inadequacies in the interpretation and extrapolation of animal data could explain the 
lack of robust effects observed with some drugs once they have advanced to clinical 
trials. First, the endpoints in preclinical studies must be carefully selected and validated 
in order to answer the questions needed for advancement to clinical studies. The choice 
of animal model should be based on the required endpoints, and the age of the animals 
included in the studies should reflect the stage of the disease at which treatment is 
intended to start.   
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Figure 5. Schematic illustration of the concepts of prevention or disease-modifying 
intervention in AD. 
 
1.4.5 Targeting nicotinic receptors 
Ongoing trials are using cholinergic drugs with nAChR agonist activity, with the 
intention of enhancing cognition and stimulating neuroprotection. Treatment of mild to 
moderate AD with nicotinic agonists selective for α4β2 nAChRs has resulted in some 
effects on cognition (Dunbar et al., 2007). However, recent clinical trials have been 
terminated because of the poor recruitment status of the patients. α7 nAChR agonists 
are also currently being tested. The partial α7 nAChR agonist EVP-6124 was well 
tolerated in preclinical trials and a phase II clinical trial (Misra and Medhi, 2013). 
Results from the phase II 6-month trial in subjects with mild to moderate AD indicate 
promising benefits, as measured with a battery of cognitive tests (Hilt et al., 2012), but 
await publication. So far, preclinical studies of α7 nAChR agonists have 
demonstrated improvements in long-term memory, but subsequent clinical trials have 
only shown attention benefits (Thomsen et al., 2010). The possible explanations for 
this discrepancy are currently under debate. Unlike ACh, α7 nAChR agonists are not 
degraded but constantly activate and desensitize the receptor. This results in an 
inverse U-shaped dose-response curve, which makes drug administration challenging 
(Geerts, 2012). Furthermore, treatment duration has typically been short, perhaps too 
short to observe any potential α7 nAChR-mediated neuroprotective actions.  
 
1.4.6 Stimulating regeneration as a potential treatment strategy for AD 
The stimulation of neurotrophic processes and repair mechanisms in the brain is a 
novel and promising approach to the treatment of AD. The term regeneration refers to 
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the repair of tissue through either stimulation of intrinsic repair mechanisms or the 
transplantation of exogenous stem or progenitor cells. There is a great need for a 
deeper understanding of the balance between neurodegeneration and brain repair, and 
of the optimal timing for such treatments.  
 
Stimulating endogenenous neuroregeneration  
One of the advantages associated with strategies focused on enhancing the brain’s 
intrinsic regeneration capacity is that they enable non-invasive approaches without the 
risk of an immune response to grafted cells. Recent increases in our understanding of 
molecular mechanisms and other factors associated with the stimulation of endogenous 
neurogenesis (see section 1.3.3) have enabled the identification of new drug targets and 
the development of new therapeutic interventions. Growth factors such as BDNF and 
nerve growth factor (NGF) are potent stimulators of endogenous neurogenesis, and are 
regarded as promising in this respect. In the first study of its kind, intraventricular 
injection of NGF into three AD patients has demonstrated increased 11C-nicotine 
retention and increased glucose metabolism (Eriksdotter Jonhagen et al., 1998; Olson et 
al., 1992). However, the route of administration had to be reconsidered because of the 
development of spinal pain in the recipients. In a later study, genetically modified 
fibroblasts secreting NGF implanted into the forebrains of eight AD patients were 
shown to be safe after 22 months' follow-up (Tuszynski et al., 2005). In a more recent 
study, six AD patients underwent basal forebrain transplantation of bio-vehicles 
containing NGF-secreting fibroblasts. This procedure was deemed safe and well 
tolerated (Eriksdotter-Jonhagen et al., 2012). The effects on cognition, however, have 
yet to be reported.  
Drugs such as antidepressants or atypical antipsychotics are reported to 
enhance neurogenesis in the brains of both rodents and humans (Nasrallah et al., 2010; 
Newton and Duman, 2007; Sahay and Hen, 2007; Santarelli et al., 2003). Preclinical 
data from studies in rodents  suggest that endogenous factors such as estrogens may also 
stimulate neurogenesis (Tanapat et al., 1999). Extrinsic factors such as physical activity 
(Ho et al., 2009; Kempermann et al., 1998; Snyder et al., 2009) and an enriched 
environment (Brown et al., 2003; Kempermann et al., 1998) that have been shown to 
stimulate neurogenesis and synaptic plasticity in rodents could also provide important 
therapeutic strategy implications for AD.  
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Transplantation of stem cells or fetal grafts 
Generally, exogenous cell replacement strategies have several advantages over other 
approaches. Large numbers of cells can be implanted and the source of the cells can be 
selected and optimized in vitro prior to grafting. However, given the widespread 
pathology and neurodegeneration resulting from these procedures, cell replacement 
strategies for AD have been considered unrealistic in comparison with their use in other 
diseases involving neurodegeneration in limited areas of the brain, such as the loss of 
dopaminergic neurons in the substantia nigra in Parkinson's disease (Lindvall et al., 
1988; Morizane et al., 2008). To date, only a limited number of studies in animal 
models of AD have explored the outcomes of stem cell transplantation. For example, 
improved cognition and enhanced synaptic density were observed following 
hippocampal transplantation of mouse neural stem cells (NSCs) in 3xTg-AD mice, and 
these positive effects were associated with increased BDNF secretion (Blurton-Jones et 
al., 2009). Moreover, improved spatial memory following NSC transplantation has 
been observed in rats with cholinergic lesions (Moghadam et al., 2009; Park et al., 
2012a; Park et al., 2012b). 
Viewing stem cell therapy for AD solely as cell replacement poses great 
challenges, since this requires extensive migration of the graft to degenerated areas in 
the brain, and subsequent differentiation and integration into functional networks. 
Recent work, however, suggests that stem cell transplantation could also generate 
trophic support for endogenous progenitor cells and neurons in the brain (Blurton-Jones 
et al., 2009; Einstein and Ben-Hur, 2008). Thus, stem cells could be regarded as 
delivery vehicles for providing the brain with a myriad of neurogenic factors.  NSC 
transplantation into the brains of animal stroke models has been shown to stimulate 
endogenous neurogenesis (Jin et al., 2011), but this has not yet been studied in AD 
animal models.  
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2 AIMS OF THE THESIS 
The main aim of this thesis was to investigate neuroprotective and regenerative 
processes in the brain, along with implications arising from this for the development of 
novel treatment strategies for AD. In vitro cellular model systems, postmortem human 
brain tissue studies, and in vivo studies in an AD transgenic mouse model were used to 
investigate neuroprotective and regenerative mechanisms in relation to the pathological 
processes associated with AD (figure 6).  
 
The specific objectives were the following: 
 
Paper I To investigate the neuroprotective role of α7 nAChRs against Aβ-mediated 
neurotoxicity and the roles of different forms of Aβ in the interactions with 
nAChRs.  
 
Paper II  To characterize the neuroprotective and neurotrophic actions of amyloid- 
modulatory candidate drugs (–)- and (+)-phenserine.  
 
Paper III To investigate the effects of modulating brain Aβ levels at different stages of 
amyloid pathology on synaptic function, hippocampal neurogenesis, and 
inflammatory cell changes. 
 
Paper IV   To investigate the effects of stem cell transplantation and modulation of Aβ 
and α7 nAChRs on endogenous neurogenesis, graft survival, and cognition. 
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Figure 6. Schematic outline of the work undertaken in the thesis. 
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3 METHODOLOGY 
In the following section, model systems and methods used in papers I–IV and in 
previously unpublished pilot studies are discussed in relation to their advantages and 
limitations. Some methodology is summarized here, but detailed descriptions of 
experimental procedures are provided in the respective papers.  
 
 
3.1 ETHICAL CONSIDERATIONS 
Human autopsied brain tissue was obtained from the Netherlands brain bank; 
permission to use this tissue in experimental procedures was granted by the Ethics 
Committee Review Board at Karolinska Institutet and the Swedish Ministry of 
Health (S024/01). All materials and data collected by the Netherlands brain bank 
were obtained on the basis of written informed consent. All animal experiments were 
carried out in accordance with the guidelines published by the Swedish National Board 
for Laboratory Animals. Ethical applications were approved for the drug treatment and 
isolation of progenitor cells and primary neurons from Tg2576 mice (S43/07, S53/10), 
and for human (h)NSC transplantation and MWM tests using Tg2576 mice (S54/10 
and S172/11).   
 
 
3.2 COMMENTS ON MODEL SYSTEMS USED 
3.2.1 Cell cultures 
The advantage of using immortal cell lines is that they are easy to expand in sufficient 
quantities for viability assays and receptor-binding experiments. Moreover, immortal 
cell lines have been well characterized and are widely used in in vitro model systems for 
molecular and mechanistic studies. The neuronal cell lines used in paper I were 
selected for their expression of α7 nAChRs. Pheochromocytoma PC12 cells undergo 
neuronal differentiation with neurite outgrowth after exposure to NGF. These cells 
were used to study α7 nAChR-mediated neuroprotection, while human neuroblastoma 
SH-SY5Y cells were used to assess intracellular calcium levels ([Ca2+]i) following α7 
nAChR agonist and Aβ exposure. Wild-type and APPswe-transfected SH-SY5Y cells 
were also used in paper II to assess neuroprotective and neurotrophic drug actions. 
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The advantages of SH-SY5Y cells are that they are of human origin and they are 
adherent in comparison with the semi-adherent PC12 cells, which makes them more 
suitable on a practical level for calcium measurements in single cells using confocal 
microscopy. However, these tumor cell lines are limited as model systems for AD since 
they do not reflect the nature of neurons in the brain and are relatively insensitive to the 
physiological concentrations of Aβ found in AD. Therefore, primary progenitor cells 
and neurons were used in the relevant in vitro studies in paper II and in the pilot studies 
for paper IV.  
In paper II, primary progenitor cells were isolated from the SVZ of Tg2576 
mouse embryos, cultured in neurospheres, and used in in vitro studies of cell survival and 
growth. The translational relevance of these cells was assessed by measuring the early 
neuronal marker doublecortin (DCX) in the SVZ of adult Tg2576 mice.  
An in vitro pilot study before the studies reported in paper IV investigated the 
effects of several classes of drugs with different mechanisms of action including the 
amyloid-modulatory drug (+)-phenserine and the α7 nicotinic agonist JN403, on the 
proliferation and neuronal and glial differentiation of hNSCs derived from fetal brains. 
Cortical primary Tg2576 neurons in culture were also investigated in this pilot study 
to assess the effects of the drugs on neuronal maturation. hNSCs transplanted into the 
hippocampi of Tg2576 mice either alone or in combination with drug treatment were 
subsequently assessed in vivo in paper IV.  
 
3.2.2 Postmortem human brain tissue 
Although human autopsied brain tissue reflects the end stage of the disease, it is an 
irreplaceable ex vivo tool for studying disease processes in humans. The postmortem 
delay should be kept as short as possible, and limitations such as the sometimes 
substantial differences between individual subjects should be carefully considered when 
designing experiments. Another issue that must be taken into consideration is that some 
subjects will have been treated with drugs that could enhance neurogenesis in the brain, 
as reviewed in section 1.3.3. Autopsied human brain tissue extracts from 5 AD subjects 
(mean age 70 y; mean postmortem delay 7 h) and 5 control subjects (mean age 67 y; 
mean postmortem delay 9 h) were used in paper I for receptor binding assays and in 
pilot studies carried out prior to paper IV to assess the viability and differentiation of 
hNSCs in culture. Extracts containing as low as picomolar concentrations of Aβ were 
sufficient to significantly decrease the viability of primary cells, which is much more 
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relevant for mirroring an AD-like environment in vitro than the recombinant Aβ 
peptides used in paper I.  
 
3.2.3 Tg2576 mice 
Despite the limitations associated with using transgenic mice in translational AD 
research studies, these mice are valuable in vivo models for studying the evolution from 
birth of molecular pathological changes since it is not possible to study these changes in 
living patients. Mice expressing the APP Swedish mutation (APPSWE2576Kha; 
Tg2576) show high levels of soluble oligomeric Aβ in the brain, up to the age of 
approximately 10 months, before the Aβ plaques begin depositing. Tg2576 mice also 
show reduced levels of the synaptic marker synaptophysin and memory impairment 
(Lithner et al., 2011; Mustafiz et al., 2011; Stewart et al., 2011; Unger et al., 2006). In 
papers II–IV, Tg2576 mice were used to model the relationship between Aβ 
pathogenesis and regenerative processes in the brain, and the ways in which these 
processes can be modulated through pharmacological treatment or by stem cell 
transplantation. The mice were bred in the Karolinska Institutet animal care facility 
by backcrossing with B6SJL (F1) females (Taconic). Wild-type littermates served as 
control animals. All mice were housed in enriched cages with a 12-hr light-dark cycle 
and ad libitum access to food and water.  
 
 
3.3 EXPERIMENTAL PROCEDURES 
3.3.1 Receptor-binding assays 
Postmortem brain tissue from AD and control subjects was used to study the interaction 
between Aβ and nAChRs, using the radioligands [3H]PIB (which binds selectively to 
fibrillar Aβ (Ni et al., 2013)), [125I]Aβ1-40, and [3H]epibatidine (an nAChR ligand) 
(paper I). For the [3H]PIB binding assays, frontal corticex tissue was homogenized in 
PBS to yield a crude membrane fraction that included the extracellular matrix. For 
the [3H]epibatidine and [125I]Aβ1-40 binding assays, membrane (P2) fractions from 
AD and control autopsied frontal cortices, with the extracellular matrix removed from 
the fraction, were used as previously described (Marutle et al., 1998). The membrane 
fractions were incubated with the radioligand, the reactions were terminated by 
filtration, and the radioactivity was counted.   
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3.3.2 Aβ preparation and characterization 
Recombinant Aβ was used in paper I, wheras Aβ assemblies in TBS extract from 
human autopsied brain tissue were used for the in vitro pilot study prior to paper 
IV. To obtain recombinant fibrillar Aβ aggregates, Aβ1-40 and Aβ1-42 (Sigma, St 
Louis, MO, USA) were dissolved in H2O and DMSO, respectively, and incubated at 
37◦C with agitation for 48–72 h before use. Recombinant soluble Aβ oligomers were 
obtained by dissolving 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP)-pre-treated Aβ1-40 
and Aβ1-42 peptides (rPeptide, Bogart, GA, USA) in DMSO, and then sonicating 
and filtering them to yield a pure, homogeneous oligomeric fraction. Recombinant 
Aβ was characterized using western blotting to verify that oligomeric Aβ remained 
non-fibrillized throughout the experiments. The aggregation and fibrillization 
processes of HFIP-pretreated oligomeric Aβ in the different buffers were assessed 
using thioflavin T (ThT) fluorescence assays. ThT assays are widely used to profile 
protein fibrillization over time, by measuring the intensity of fluorescence emitted 
from ThT when it binds to fibrillizing protein. For the pilot study, a water-soluble 
TBS fraction of Aβ oligomers was extracted from autopsied brain tissue from a patient 
with AD and a healthy control as described previously (Bao et al., 2012). Aβ assemblies 
in these fractions were characterized according to size using western blotting and 
ADDL-specific antibodies.  
 
3.3.3 Viability assays 
In MTT and MTS proliferation assays, a tetrazolium compound (MTT or MTS) is 
reduced to formazan by nicotinamide adenine dinucleotide phosphate (NADPH) or 
nicotinamide adenine dinucleotide (NADH) dehydrogenase enzymes in metabolically 
active cells. The amount of formazan product, measured by absorbance, is directly 
proportional to the number of living cells (papers I and II). In paper II, MTS 
reduction was also used as a measure of cell proliferation. In paper I, MTT assays 
were complemented by measuring the release of lactate dehydrogenase (LDH) from 
cells with cell membrane leakage (CytoTox ONE Homogeneous Membrane Integrity 
Assay, Promega, Stockholm, Sweden). LDH release is a valuable complementary test 
for viability which measures the amount of non-viable cells in the samples. Formation 
of the fluorescent product resorufin is then proportional to the amount of LDH 
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released.   
 
3.3.4 Intracellular calcium measurements 
In paper I, we monitored α7 nAChR activation and the subsequent influx of Ca2+ 
ions by measuring changes in [Ca2+]i in SH-SY5Y cells, using the calcium indicator 
Fluo-3. Although Fluo-3 is a widely used dye, it is non-ratiomeric and therefore its use 
is limited compared to ratiomeric dyes that have dual emissions to enable the use of 
an internal reference. SH-SY5Y cells were loaded with Fluo-3 AM (Invitrogen), an 
ester conjugate to facilitate penetration of the cell membrane, and excited using an 
inverted Meta-Zeiss 510 LSM confocal microscope (Carl Zeiss, GmbH, Germany). 
Recordings were taken during 60 min of incubation at room temperature and the 
fluorescence intensity was measured continuously throughout the incubation period.  
 
3.3.5 Detection and quantification of protein expression 
Antibody detection-based methods of protein detection or quantification were used in 
all the papers. Western blotting was used to separate Aβ assemblies in Aβ preparations 
and autopsied human brain tissue extracts according to size (papers I and in the pilot 
study prior to paper IV) and to quantify synaptophysin protein levels (paper III). 
While western blotting is an excellent tool for protein detection and separation of 
proteins by size, it is considered a semi-quantitative method. Enzyme-linked 
immunosorbent assays (ELISA), a conventional quantitative method, were used in 
papers II–IV to measure protein levels in mouse brain tissue extracts. A similar 
quantitative method, using Meso Scale Discovery (MSD) technology, was used in 
paper III to measure cytokine and chemokine levels in mouse brain cortical tissue 
extract, and in the pilot study related to paper III for quantification of mouse Aβ 
CSF levels. MSD technology is based on the capture and detection of antibodies to 
detect epitope-specific antigens. In contrast to regular ELISA, which uses enzyme-
linked detection antibodies to yield fluorescent or color signals upon addition of 
substrate, MSD technology uses ruthenium-conjugated detection antibodies that emit 
light upon electrochemical stimulation of the electrode surface in the microplate. 
Multiple excitation cycles enhance the chemoluminiscence signal and further improve 
the sensitivity of this technique.   
For the pilot study for paper IV, immunocytochemistry was used to detect, 
quantify and morphologically characterize glial and neuronal phenotypes of 
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differentiated hNSCs in culture. Immunohistochemistry was also used in paper IV to 
study the regional distribution of astrocytes in coronal brain sections, which allowed 
quantification of the number of α7 nAChR-expressing astrocytes specifically in the DG 
of the hippocampus, and characterization of their morphological phenotypes in 
different regions of the DG.  
 
3.3.6 Drug treatment  
The full α7 nAChR agonist and α4β2 partial agonist varenicline, and the partial α7 
nAChR agonist JN403 (Coe et al., 2005; Feuerbach et al., 2007; Mihalak et al., 2006) 
were used as tools to study the interactions of Aβ with α7 nAChRs in neuronal cell lines 
and in postmortem brain tissue (paper I). As JN403 is a more selective α7 nAChR 
agonist than varenicline, this drug was also given by intraperitoneal (i.p.) injection (0.3 
mg/kg) in paper IV to treat Tg2576 mice in combination with hNSC transplantation.    
In paper II, the AChEI (–)-phenserine, its cholinergically inert 
enantiomer (+)-phenserine, and the primary metabolites of (+)-phenserine (+)-N1-
norphenserine, (+)-N8-norphenserine and (+)-N1,N8-bisnorphenserine were 
characterized in vitro with regard to their neuroprotective and neurotrophic properties. 
To avoid interference from cholinergic actions, (+)-phenserine was selected to study the 
effects on neurotrophic actions and on Aβ pathology in Tg2576 mice (i.p. injections of 
25mg/kg (+)-phenserine once daily) (papers II–IV).  
 
3.3.7 Transplantation and CSF collection 
In paper IV, Tg2576 mice received bilateral hippocampal injections transplanting 
25,000 hNSCs per hemisphere or vehicle (coordinates relative to bregma: AP -2.06, 
ML ±1.75, DV -1.75). The mice were anesthetized using a constant flow of 4% 
isoflurane throughout the procedure. The heads of the mice were fixed using ear and 
tooth bars before a skin incision into the skull bone was made to facilitate the location of 
the coordinates to target the DG of the hippocampus. Lidocaine was used for local 
anesthesia during the procedure and the animals were monitored daily for body weight 
and healing of the incision site after the surgery. While the use of immunosuppressants 
helps to avoid the risk of graft rejection after transplantation procedures, 
immunosuppressants can affect inflammatory processes and their use should be 
carefully considered in the study design. Stem cells could play an immunomodulatory 
role per se (Einstein and Ben-Hur, 2008), and previous studies have indicated that 
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transplantation of hNSCs into the brains of APP transgenic mice does not require the 
use of immunosuppressants (Marutle et al., 2007) for studies with a time-frame similar 
to that in paper IV. Accordingly, no immunosuppressants were used, and no 
symptoms indicative of a reaction to the transplant were observed.  
For the pilot study relavant to paper III, CSF was collected from the cisterna 
magna of 4- to 6-month-old Tg2576 mice. The animals were anesthetized with a 1:1 
mixture of ketamine (100 mg/kg) and xylazine (20 mg/kg), and a 26 gauge needle 
connected to a syringe by a P20 polyethylene tube was used to collect up to 7 µl CSF 
per mouse. The animals were euthanized by decapitation, and the CSF was frozen and 
stored at -80°C until used for Aβ measurements. 
 
3.3.8 Behavioral tests 
MWM tests were used to assess the hippocampal-dependent spatial memory of Tg2576 
mice and their age-matched wild-type littermates, and of Tg2576 mice after 
hippocampal hNSC transplantation (paper IV). The mice were placed in water at 
random sites (four fixed positions) around the wall of a round swimming pool of 1 m 
diameter. During the acquisition phase, the mice learned the location of a platform 
hidden under the water, aided by visual cues on the walls around the pool. In order to 
assess retention of this spatial memory, a probe trial was performed 24 hours after the 
last acquisition trial; in this, the platform was removed and the mice were allowed to 
swim for 60 seconds. The behavior of the mice in the MWM task was recorded by an 
automated video-tracking system (Ethovision). To evaluate differences in learning and 
memory between groups, Δ-latency values were calculated (follow-up probe values 
minus baseline acquisition values).  The advantage of using the MWM to assess 
learning and memory in these mice is that it is a well-recognized behavioral test that has 
been widely used to characterize cognitive deficits in Tg2576 mice. Since impaired 
motor behavior or poor vision could greatly influence the performance of the mice in 
the MWM, the mice should be carefully monitored prior to testing. The pool size 
should also be selected carefully; since the smaller the pool, the easier it is for the mice 
to find the hidden platform.  
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3.3.9 Statistics 
GraphPad Prism 5.0 or 6 (GraphPad Software, Inc.) was used for all statistical analyses.  
In all papers, parametric tests were used to compare statistical differences between 
treatment groups in the in vitro studies using cell cultures or tissue homogenates, whereas 
non-parametric tests were used for analysis of data from Tg2576 mice.  
One-way ANOVA followed by Bonnferroni’s or Dunnet’s post-hoc tests was used to 
compare statistical differences between treatment groups in papers I and II, the non-
parametric Mann-Whitney test or Student’s t-test was used for comparison between 
two groups, and the non-parametric Kruskal-Wallis one-way ANOVA by ranks 
followed by Dunns or Dunnet’s post-hoc test was used for comparison between multiple 
(>2) groups in papers III and IV). Spearman’s rank correlation was used as a non-
parametric test for correlation analysis, which was visualized graphically using simple 
regression analysis (papers III and IV). In all papers, the data are presented as means 
± standard error of the mean (SEM). P-values <0.05 were considered to be significant. 
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4 RESULTS AND DISCUSSION 
This section summarizes and discusses the main findings of the thesis. A more detailed 
description of the results can be found in the respective papers.  
 
 
4.1 INTERACTION OF FIBRILLAR AND OLIGOMERIC FORMS OF Aβ 
WITH α7 nAChRs – RELEVANCE FOR NEUROPROTECTION 
Mounting evidence suggests that the continuous loss of nAChRs in the hippocampi and 
cerebral cortices of patients with AD could be mediated through an interaction between 
α7 nAChRs and Aβ species (Jonnala and Buccafusco, 2001; Kihara et al., 2001). An 
exciting field of research postulating the potential advantages of targeting α7 nAChRs 
to induce neuroprotective mechanisms against Aβ-induced toxicity has recently 
emerged. Comparative studies on the effects of Aβ1-40 versus Aβ1-42 are sparse but 
available studies indicate that Aβ1-40 interacts with α7 nAchRs in a reversible manner, 
whereas Aβ1-42 binds to the receptor irreversibly (Lee and Wang, 2003). The 
importance of the assembly form of Aβ on the interaction with α7 nAChRs is an 
important aspect that has not to our knowledge been investigated previously. The 
interactions between different aggregated forms of Aβ and α7 nAChRs were thus 
studied in paper I, using neuronal cells in culture and postmortem human brain tissue 
from AD patients. This study indicated that recombinant fibrillar Aβ1-40 causes 
cytotoxic effects in PC12 cells, whereas fibrillar Aβ1-42 and oligomeric Aβ1-40 and 1-
42, in the form of dimers, decamers, dodecamers and larger oligomers of approximately 
100 kDa in size, did not significantly reduce cell viability at physiologically relevant 
concentrations (nanomolar range), as reflected in the brains of sporadic AD patients 
(Hashimoto et al., 2010).  
It has been suggested that α7 nAChRs exert neuroprotective effects 
through downstream signalling pathways such as i) the MAPK/ERK signaling pathway 
and activation of the downstream transcription factor CREB, or ii) the PI3K/Akt 
pathway, both of which are important for neurotrophic actions and cell survival 
(Abbott et al., 2008; Bell et al., 2004; Dineley et al., 2002; Dougherty et al., 2003). For 
further details, the reader is referred to section 1.1.3 Amyloid-β interactions with nicotinic 
receptors. Paper I showed that the partial α4β2 and full α7 nAChR agonist varenicline 
and the partial α7 nAChR agonist JN403 protected the cells against fibrillar Aβ1-40-
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induced toxicity, further indicating that α7 nAChRs mediate neuroprotective effects. 
We then hypothesized that these effects could be mediated a) through the signalling 
mechanisms mentioned above, b) by preventing Aβ from binding to nAChRs, or c) by a 
combination of these.    
Using a human postmortem frontal cortex tissue homogenate, we found 
that [125I]Aβ1-40 bound to α7 nAChRs. To further investigate the interaction between 
fibrillar Aβ and α7 nAChRs, we studied the effects of varenicline and JN403 on 
[3H]PIB binding to Aβ in AD frontal cortex autopsied brain tissue. 3H-PIB binds 
selectively to, and correlates with levels of, fibrillar Aβ at autopsy (Kadir et al., 2011; Ni 
et al., 2013). [3H]PIB binding increased after exposure to these two compounds, 
possibly reflecting the displacement of Aβ from α7 nAChRs by α7 nAChR agonists, 
thus making the “free” or non-complex-bound Aβ more accessible for binding to 
[3H]PIB (figure 7). A recent study using drugs with affinity for different nAChR 
subtypes confirmed the specific binding to α7 nAChRs (Ni et al., 2012). 
 
 
Figure 7. Illustration of a proposed interaction between fibrillar Aβ and α7 nAChRs 
in the presence of α7 nAChR ligands (modified illustration courtesy of Ruiqing Ni, 
Karolinska Institutet, Sweden).  
 
The role of oligomeric Aβ in the interaction with α7 nAChRs was then tested by 
displacing the nAChR ligand [3H]epibatidine with varenicline in the presence of 
oligomeric Aβ1-40 using a human postmortem frontal cortex tissue homogenate. 
Interestingly, the presence of 0.1 and 5 µM oligomeric Aβ1-40 resulted in a receptor 
occupancy of approximately 50 %. In addition, a shift in the affinity of varenicline to 
nAChRs from the pM to µM range was observed in the presence of 5µM Aβ1-40 
(figure 8). This suggests that oligomeric Aβ modulates nAChRs allosterically and 
possibly changes the conformation of the receptor, which consequently alters the 
binding affinity of nAChR ligands. This finding, together with the observation of 
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increased [3H]PIB binding, could shed light on current research aiming to develop α7 
nAChR-positive allosteric modulators for AD treatment. At least one of these novel 
compounds, S24795, has been shown to prevent or reverse the binding of Aβ to α7 
nAChRs (Wang et al., 2010; Wang et al., 2009), indicating that this type of drug 
could potentially preserve or potentiate the receptors’ neuroprotective properties. It is 
suggested that varenicline and JN403 could display similar features.  
To date, one study has modeled the interaction of Aβ with α7 nAChRs 
at the molecular level. Multiple binding sites were identified, and at least one Aβ-
epitope was accessible for α7 nAChR binding in various Aβ species ranging from 
monomers to protofibrils. This epitope, named K28, binds to the same site as ACh, 
whereas other Aβ binding sites seem to be located on the periphery of α7 nAChRs 
and do not interfere with ACh binding (Maatuk and Samson, 2013). Hence, there is 
reason to expect that Aβ could modulate α7 nAChRs either allosterically or at the 
active site.   
 
Figure 8. Oligomeric Aβ1-40 decreases the affinity of varenicline for nAChRs in the 
human frontal cortex. Reprinted from Lilja et al. (Lilja et al., 2011), with permission 
from IOS Press.  
 
To further assess the functional effects of oligomeric Aβ on nAChRs, [Ca2+]i was 
measured in SH-SY5Y cells after exposure to Aβ1-40 and varenicline. Oligomeric but 
not fibrillar Aβ increased [Ca2+]i, with a maximum response at 10 nM. This effect 
was attenuated by varenicline, suggesting that oligomeric Aβ1-40 activates α7 nAChRs 
to modulate Ca2+-dependent synaptic function. This is in line with previous findings 
showing that Aβ1-42 elevates Ca2+ levels through neuronal α7 nAChRs (Dougherty et 
al., 2003), and also indicates that varenicline prevents Aβ from binding to α7 nAChRs.   
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Taken together, these findings suggest that the α7 nAChRs are an important 
cellular target for Aβ, and that the aggregated form of Aβ is relevant to its effect on α7 
nAChRs. It appears that some of the multiple Aβ binding sites characterized by 
Samson and Maatuk operate independently of the Aβ aggregation state, whereas other 
binding sites are specific for particular assembly forms and thus contribute to their 
unique properties.  In the model systems studied in this thesis, fibrillar Aβ interacted 
with α7 nAChRs to induce neurotoxic effects, whereas oligomeric Aβ seemed to 
modulate synaptic function through the alteration of  [Ca2+]i. Hence, it appears that 
targeting α7 nAChRs in order to stimulate neuroprotective actions against Aβ-induced 
toxicity will depend on the stage of amyloid pathogenesis at which the intervention is 
introduced.  
 
 
4.2 STIMULATION OF REGENERATIVE PROCESSES AND THE 
IMPORTANCE OF Aβ MODULATION 
Several studies, both in vitro (Haughey et al., 2002; Kwak et al., 2011; Wicklund et al., 
2010) and in vivo (Zheng et al., 2013), have suggested that the pathophysiological 
environment in AD has adverse effects on stem cells and neurogenesis. In order to 
investigate the translation of in vitro results from cellular models of pharmacological 
modulation of Aβ on endogenous neurogenesis and synaptic function, in vivo studies 
using Tg2576 mice of different ages were carried out. The two experimental AD drugs 
(–)- and (+)-phenserine, both of which are APP synthesis inhibitors and thus lower Aβ 
levels (Greig et al., 2005; Lahiri et al., 2007; Mikkilineni et al., 2012; Shaw et al., 
2001), were investigated.  
 
4.2.1 (+)-Phenserine stimulates neuroprotective and neurotrophic processes via 
MAPK signaling and enhanced BDNF levels 
The aims of Paper II were to characterize the neuroprotective and neurotrophic 
effects of (–)- and (+)-phenserine, and the primary metabolites of (+)-phenserine: (+)-
N1-norphenserine, (+)-N8-norphenserine and (+)-N1,N8-bisnorphenserine, and also to 
investigate the primary signaling pathways responsible for mediating these effects. All 
the compounds lower APP levels through translational inhibition of the IL-1 response 
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element in the 5’ untranslated region of the APP mRNA (Mikkilineni et al., 2012; Shaw 
et al., 2001; Yu et al., 2013) (figure 9).  
  
 
Figure 9. Chemical structures of phenserine and its primary metabolites, and 
schematic illustration of APP inhibition.  
 
(+)-Phenserine, (–)-phenserine and (+)-N1-norphenserine increased the proliferation of 
SH-SY5Y cells. (+)-Phenserine had sustained effects on cell proliferation in the presence 
of sub-lethal levels of Aβ and H2O2, and displayed neuroprotective effects against 
H2O2- and glutamate-induced toxicity. (+)-Phenserine also enhanced cell proliferation 
and demonstrated pro-survival effects in primary Tg2576 progenitor cells in culture. 
Both the proliferative and neuroprotective actions were mediated, at least in part, 
through the protein kinase C (PKC) and MEK signaling pathways. MEK1 and MEK2 
signaling are closely involved in the regulation of cell proliferation and cycle arrest, and 
MEK2 is especially known to promote cell survival. PKC acts upstream from MEK 
and is thus also closely involved in the regulation of these cellular processes (Skarpen et 
al., 2008; Ussar and Voss, 2004).  
Merging evidence suggests that BDNF plays an important role in promoting 
neuroprotection in rodents and primates (Nagahara et al., 2009). It activates the 
MAPK/ERK signaling pathway, which in turn activates the downstream transcription 
factor CREB. CREB then promotes the expression of BDNF through a positive feed-
back loop (Autry and Monteggia, 2012; Lu et al., 2008). Interestingly, we measured 
increased BDNF levels in the cerebral cortices of wild-type mice after (+)-phenserine 
treatment. Our findings thus indicate that (+)-phenserine exerts actions involving 
MAPK signaling pathways, including enhancement of BDNF levels.  
 
4.2.2 Modulation of Aβ levels in the cerebral cortices and CSF of Tg2576 mice 
The effects of (+)-phenserine on Aβ levels at different stages of amyloid pathology and 
the subsequent effects on synaptic function, hippocampal neurogenesis and 
inflammatory cell changes were investigated in paper III and its related pilot study. 
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In paper III, reductions in Aβ1-42 levels were observed in both 4- to 6-month-old and 
15- to 18-month-old Tg2576 mice that received (+)-phenserine for 16 consecutive days. 
The effects of (+)-phenserine on Aβ levels in the CSF of 4- to 6-month-old APPswe 
transgenic mice were investigated in the pilot study. The levels of Aβ1-42 were 
reduced (by 26 %) as was the Aβ42/40 ratio (by 21 %) in the (+)-phenserine-treated 
mice, but the difference did not reach statistical significance (figure 10). Clinical data 
have shown similar but more pronounced reductions in CSF Aβ1-42 levels after 10 
days of (+)-phenserine administration to MCI patients (Maccecchini et al., 2012). 
 
 
   
Figure 10. Aβ levels in (A) cerebral cortex and (B) CSF of 4- to 6-month-old Tg2576 
transgenic mice treated with (+)-phenserine (Phe) or saline (Sal). Data are shown as 
mean values ±SEM.  
 
4.2.3 Modulation of chemokine and cytokine levels in Tg2576 mouse brains 
Because Aβ is known to stimulate the activation of microglia and astrocytes and the 
release of pro-inflammatory cytokines (Combs et al., 2001; Lindberg et al., 2005; 
Meda et al., 1995), we examined the effects of (+)-phenserine on the pro-
inflammatory cytokines IL-1β and TNFα, and the chemokine MCP-1. Levels of IL-
1β were elevated in Tg2576 mice compared to wild-type mice in both age groups; 
(+)-phenserine attenuated this increase in the older Tg2576 mice (15–18 months old). 
MCP-1 induces astrocyte chemotaxis and contributes to the recruitment of astrocytes 
around Aβ plaques (Wyss-Coray et al., 2003). Interestingly, we found age-dependent 
increases in cortical MCP-1, and an association between MCP-1 levels and lowered 
Aβ1-42 levels in the older Tg2576 mice. TNFα has been implicated in both the 
A B 
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pathogenesis of AD (Combs et al., 2001; Tarkowski et al., 2003a; Tarkowski et al., 
2003b) and the mediation of neuroprotective effects through increased production of 
neurotrophic factors (Hattori et al., 1993; Sriram and O'Callaghan, 2007). In line 
with the latter, a trend towards increased TNFα levels was observed in (+)-
phenserine-treated Tg2576 mice in both age groups.  
 
4.2.4 Enhanced cell proliferation and DCX expression in the neurogenic zones of the 
brain 
(+)-Phenserine treatment of the younger Tg2576 mice resulted in increased numbers 
of BrdU+ proliferating cells in the CA1 region of the hippocampus, a region 
especially vulnerable to Aβ (Burger, 2010), and also a trend towards increased 
numbers in the DG. A similar increase in BrdU incorporation was shown in the older 
Tg2576 mice after (+)-phenserine treatment. The increased cell proliferation in both 
age groups was associated with attenuated Aβ1-42 levels in the brains of these mice. 
Thus, reducing the Aβ load in the brains of older Tg2576 mice (15–18 months old) 
when Aβ plaque pathology is prominent could enhance cell proliferation in the 
hippocampus. 
A significant reduction in hippocampal neurogenesis was observed in the 
older mice compared to the younger treatment groups, indicating that NPCs are fewer 
or more vulnerable in older animals. Previous work has indicated that the age-
dependent decline in hippocampal neurogenesis occurs because of decreased neuronal 
maturation, decreased levels of neurotrophic factors, or aberrant vasculature in the 
vicinity of the neurogenic zone (Bernal and Peterson, 2004; Lugert et al., 2010; Shetty 
et al., 2005). Treatment of the younger (4- to 6-month-old) Tg2576 mice with (+)-
phenserine stimulated the maturation and plasticity of newborn neurons in the 
hippocampal DG (paper III; figure 11), and increased the expression of the early 
neuronal marker DCX in the subventricular zone (paper II; figure 12). Regardless of 
the location of the neurogenic zone, NPCs follow similar general patterns including 
proliferation, migration, differentiation and integration into existing networks. 
Neuroblasts in the SVZ can be induced to migrate away from their usual route to the 
olfactory bulb towards a site of injury or neurodegeneration in the cerebral cortex or 
other brain areas, as reviewed by Christie and Turnley (Christie and Turnley, 2012). In 
the DG, however, there is little if any migration to other areas of the brain in response 
to injury or disease, although neurogenesis can be induced at the site of injury, with 
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improvement in memory functions (Christie and Turnley, 2012). Hence, 
pharmacological induction of neurogenesis in both the SVZ and the DG could have 
different, and probably positive, implications for the treatment of neurodegenerative 
diseases such as AD.  
 
 
  
Figure 11. Increased dendritic arborization of newborn neurons in the DG of 4- to 
6-month-old Tg2576 mice following (+)-phenserine treatment.  
 
 
Figure 12. Increased DCX immunoreactivity in the SVZ of 4- to 6-month-old 
Tg2576 mice following (+)-phenserine treatment.  
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4.3 HUMAN NEURAL STEM CELL TRANSPLANTATION AND EFFECTS 
ON HIPPOCAMPAL NEUROGENESIS, SPATIAL MEMORY, AND α7 
nAChR-EXPRESSING ASTROCYTES   
The studies presented so far suggest that α7 nAChRs are important mediators of 
neuroprotective actions (paper I), that (+)-phenserine has neurotrophic actions in AD 
Tg2576 mice, and that early reduction of amyloid pathology could enhance 
endogenous neurogenesis (papers II and III). Although cell replacement therapies 
have in the past been regarded as highly challenging and, perhaps, not feasible for 
future treatment of patients with AD, recent experimental studies indicate that 
transplantation of stem cells into the brains of AD transgenic mice, in addition to 
increasing the levels of progenitor cells, could also supply trophic support to 
endogenous progenitor cells in neurogenic regions of the brain and to existing 
neurons (Blurton-Jones et al., 2009; Einstein and Ben-Hur, 2008). In paper IV, we 
expanded our hypothesis to examine how the stimulation of regenerative mechanisms 
in vivo is related to cognitive status in younger Tg2576 mice (a model for early Aβ 
pathological changes in AD).  
 
4.3.1 Pharmacological stimulation and neuronal induction in AD-like brain 
microenvironments  
An in vitro pilot study was carried out before paper IV to select suitable drugs for 
pharmacological treatment. We investigated the neuroprotective and neurotrophic 
effects of various drugs: the α7 nAChR partial agonist JN403, the amyloid-modulatory 
drugs (–)-phenserine and (+)-phenserine, the antidepressant fluoxetine, the anti-
inflammatory ibuprofen, and the AChE and α7 nAChR allosteric modulator 
galantamine. After 28 days of hNSC differentiation in culture, the number of cells 
positive to the neuronal marker βIII-tubulin was markedly reduced after exposure to a 
TBS extract from AD frontal cortex containing picomolar concentrations of Aβ, 
compared to untreated cells. Drug treatment with nanomolar concentrations of JN403 
alleviated these effects to a large extent (figure 13A and B). When given in combination 
with similar concentrations of (+)-phenserine, JN403 also promoted neuronal 
maturation of Tg2576 primary corticex neurons (figure 13 C and D). The primary 
neurons were also stained for synaptophysin after JN403 exposure, but were not 
quantified due to the diffuse distribution of this marker (figure 14 A-C).  JN403 and 
(+)-phenserine showed the most potent neurotrophic effects among the drugs studied, 
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and were selected for in vivo studies of hNSC transplantation of Tg2576 mice (paper 
IV), as described in the following section.  
 
 
Figure 13. (A) Expression of neuronal marker βIII-tubulin (red) and glial marker 
GFAP (green) in hNSCs in vitro after 28 days' differentiation. The hNSCs were 
untreated (CTRL), or weekly exposed to brain extracts from a healthy control (HC), a 
patient with AD (AD), AD plus JN403 (JN), or AD plus (+)-phenserine (PHEN). (B) 
Representative images of CTRL, HC, AD, and AD+JN as outlined in (A). (C–D) 
Expression of the neuronal marker MAP2 (red) and the number of branch points in 
untreated Tg2576 transgenic mouse primary cortex neurons in culture (CTRL) and 
after weekly exposure to JN403 (JN), (+)-phenserine (PHEN), or JN403 plus (+)-
phenserine (JN+PHEN) for 21 days. **p<0.01 compared with CTRL, #p<0.05, 
##p<0.01 compared to AD. The data are expressed as means ± SEM. 
 
Figure 14. Representative images of mouse primary cortex neurons labeled for A) 
MAP2, B) synaptophysin, and C) overlay of MAP2 and synaptophysin. Arrows point 
to neuronal soma.  
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4.3.2 hNSC transplantation augments endogenous neurogenesis and improves 
cognitive function in Tg2576 mice 
Intrahippocampal transplantation of hNSCs into 6- to 9-month-old Tg2576 mice was 
combined with 5 weeks' treatment with (+)-phenserine, JN403, or vehicle.  The aims 
were to test spatial learning and memory prior to and after transplantation and drug 
treatment, and to investigate the effects of drug treatment on endogenous neurogenesis 
in the DG, hNSC transplant survival, and the number of α7 nAChR-expressing 
astrocytes in the neurogenic niche (for study design, see figure 15). Although Tg2576 
mice of this age have elevated Aβ levels and increased astrocytosis, they also exhibit a 
degree of neuroplasticity, as shown in paper III. 
Figure 15. Experimental design as presented in paper IV.  
 
hNSC transplantation ameliorated the impaired hippocampal-dependent spatial 
memory in Tg2576 mice, at least in part by enhancing endogenous neurogenesis, as 
identified by increased numbers of DCX+ neurons in the DG. Thus, these findings 
support a direct connection between endogenous neurogenesis and cognitive function. 
They also suggest that transplantation of stem cells could offer valuable support for 
existing neurons and endogenous stem cell populations in the hippocampus. In line 
with these findings, a previous study has shown that hippocampal transplantation of 
murine NSCs improves cognition mediated by increased BDNF levels in aged 3xTg-
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AD mice, despite heavy Aβ plaque and NFT pathology (Blurton-Jones et al., 2009).  
Thus, we hypothesize that impaired neurotrophic support in AD can result in impaired 
endogenous neurogenesis, which could be restored by hNSC grafts.  
 
4.3.3 Distribution of α7 nAChR-expressing astrocytes in the hippocampal neurogenic 
niche 
Although α7 nAChR-mediated neuroprotective effects have been confirmed in a 
number of experimental studies, including those in paper I, little is known about 
whether the effects are the result of α7 nAChRs expressed on neurons or on astrocytes. 
Investigations into α7nAChRs on astrocytes are few, although these include reports on 
the presence of functional α7 nAChRs on astrocytes in rat hippocampus slices 
(Sharma and Vijayaraghavan, 2001; Shen and Yakel, 2012). The density of α7 
nAChRs on neuronal cells was reduced and the number of α7 nAChR-expressing 
astrocytes surrounding Aβ plaques was increased in postmortem AD brains, indicating 
that this subset of astrocytes could play an important role in the inflammatory processes 
occurring in response to Aβ deposition (Yu et al., 2005). In the DG of hNSC-
transplanted Tg2576 mice receiving JN403, the number of α7 nAChR- expressing 
astrocytes was significantly lowered versus those receiving saline. In addition to the 
effects on astrocytes, co-administration of hNSCs and JN403 inhibited the improved 
spatial memory and the induced endogenous neurogenesis observed after hNSC 
transplantation alone. In contrast to the in vitro findings where JN403 exerted 
neurotrophic actions, it seems that JN403 has antagonistic rather than agonistic effects 
in this in vivo model system.  
Intriguingly, we found that α7 nAChR-expressing astrocytes accumulated along 
the needletrack, indicating that these cells are involved in modulating inflammation 
associated with tissue remodeling following injury. This led us to ask whether the 
numbers of α7 nChR-expressing astrocytes in the neurogenic niche could be linked 
with neurogenesis. In support of this theory, the increased number of α7 nAChR-
expressing astrocytes was found to positively correlate with the number of DCX+ 
cells in the DG. Hence, we postulate for the first time that α7 nAChR-expressing 
astrocytes could be important in tissue remodeling and plasticity. These findings also 
raise the question of whether there are any functional differences between non-α7 
nAChR-expressing astrocytes and α7 nAChR-expressing astrocytes in cell repair – 
and if so, what these differences are. Clearly, this requires further detailed 
  45 
investigation.   
 
4.3.4 (+)-Phenserine enhances graft survival but antagonizes hNSC-mediated effects 
on endogenous neurogenesis and cognition 
Treatment with (+)-phenserine increased the survival of the grafted cells, in line with 
our previous findings that this drug exerts pro-survival effects on progenitor cells and 
hippocampus neurons (paper II). In contrast, (+)-phenserine prevented the increased 
neurogenesis and the improvements in hippocampus-dependent memory induced by 
hNSC transplantation. Based on the findings in paper II, (+)-phenserine seems to 
exert neurotrophic effects through the MAPK and PKC signaling pathways, which are 
involved in a diverse repertoire of biological events including proliferation, 
differentiation, metabolism, motility, survival, and apoptosis. Consequently, this vast 
array of mechanisms could interfere with the effects of transplanted hNSCs on the brain 
microenvironment in order to support neurogenesis. Given that (+)-phenserine appears 
to enhance graft survival by acting directly on the implanted hNSCs, this effect would 
most likely not be antagonized.  
Although hNSC transplantation holds great promise, impaired graft 
survival as a result of the increasing presence of pathological proteins in the AD brain 
should be considered. Hence, to sustain the efficacy of this intervention, we propose 
that combination treatment with drugs that target the different pathological processes 
without interfering with the stem cell-mediated neurogenic effects should be 
administered at specific disease stages. Current efforts to determine the time course of 
the pathological changes during the disease, using CSF and imaging biomarkers, are 
important in this respect as the results could indicate when different types of 
regenerative and neurotrophic therapies would be most beneficial for AD patients. 
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5 CONCLUDING REMARKS AND FUTURE OUTLOOK 
The clinical implications of experimental studies investigating the stimulation of 
neuroprotection and brain repair are currently being explored. It is hoped that these 
studies will result in therapeutic strategies that will change or halt the clinical course of 
AD, in contrast to the currently available symptomatic treatment. In the translational 
approach presented in this thesis, the main aim was to investigate how neuroprotective 
and regenerative processes can be enhanced in a variety of experimental model systems 
relevant for AD, to define implications for the development of novel intervention 
strategies. 
 
Do nAChRs have differential roles in neuroprotection and neurogenesis? 
We found that α7 nAChRs play an important role in mediating neuroprotection 
against Aβ-induced neurotoxicity, and that the aggregated form of Aβ is important for 
the interaction with α7 nAChRs and the downstream effects in neuronal cells. This 
implies that the time of introduction of α7 nAChR-targeting interventions during the 
disease course determines the effects of the treatment. I postulate that α7 nAChR 
ligands that promote cell survival and neuroprotection through intracellular 
mechanisms, in combination with compounds that sterically occlude Aβ from binding 
to α7 nAChRs, would be promising treatment strategies for AD. These drugs could 
comprise positive allosteric modulators, which do not get desensitized as easily and are 
postulated to have good chances to be clinically successful.  
In addition to the neuroprotective role of α7 nAChRs, we found that the 
numbers of α7 nAChR-expressing astrocytes were related to the degree of hippocampal 
endogenous neurogenesis of stem cell-transplanted Tg2576 mice. These findings 
prompted me to wonder what roles α7 nAChR-expressing astrocytes might play in the 
neurogenic niche and with respect to tissue remodelling and plasticity, and whether α7 
nAChR-expressing astrocytes in the vicinity of neurogenic zones in the brain possess 
neurotrophic properties. These and other questions could be used in future studies on 
α7 nAChRs and elucidation of their role in regenerative processes.  
 
Therapeutic window for enhancing endogenous neurogenesis 
This thesis has also provided new insights into a number of different effects mediated by 
the amyloid modulatory drug (+)-phenserine, a current and promising candidate drug 
  47 
for AD therapy. The drug exerted neuroprotective, pro-survival and cell proliferative 
effects of neuronal and progenitor cells in culture, which translated into neuronal 
maturation of the latter cells in vivo in AD transgenic mice. These effects on 
regeneration and plasticity in the brain were achievable only during the specific time 
period when neurogenesis in the brain was still measurable and inducible. Although 
some of the data indicate an association between the effects on Aβ pathogenesis with 
those on neurotrophic processes, this should be interpreted with caution, as a causal 
relationship remains to be proven. These findings gave rise to further questions that 
require investigation. For example, can regenerative therapies prevent the age-
dependent decline in neurogenesis and preserve cognitive function, and at what stage 
during the disease course should Aβ-targeting therapies be introduced in order to halt 
or prevent amyloid pathogenesis? Given the age-dependent sigmoidal increase in Aβ 
levels (Karran et al., 2011) and previous indications that endogenous neurogenesis 
shows an exponential decline with age (Knoth et al., 2010; Lazic, 2011), interventions 
targeting Aβ or stimulating regenerative processes may be successful if introduced early 
enough during the disease course. Further investigation using (+)-phenserine to answer 
these questions would be on my wishlist. A recent research study posits that 
hippocampal neurogenesis in humans continues throughout life, with only minor 
decline associated with ageing (Spalding et al., 2013). These findings appear promising 
for the translational relevance of the results to date, and suggest that the therapeutic 
window for stimulating neurogenesis in humans is probably much broader than that in 
rodents.  
 
Endogenous neurogenesis linked to cognition 
We have shown for the first time that stem cell transplantation stimulates endogenous 
neurogenesis in an AD animal model. Enhanced neurogenesis was further associated 
with improved hippocampus-dependent memory in Tg2576 mice, indicating a link 
between endogenous neurogenesis and cognition. These findings indicate that hNSCs 
themselves possess an intricate innate signaling system, and secrete a plethora of 
neurogenic factors that could stimulate a number of processes during neurogenesis. 
Stem cell transplantation in AD patients could thus be superior in outcome to drugs 
acting at only one or even a few targets. Safety issues regarding the use of stem cell 
transplants, as well as the sustainability of the neurogenic effects observed after stem cell 
transplantation, however, needs to be studied in long-term trials. 
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In summary, this thesis indicates that the introduction of intervention strategies early in 
the disease course when i) amyloid burden is low, ii) neurogenesis is still substantial in 
the brain, and iii) memory deficits are mild, will enable detection of neuroprotective 
and neurotrophic effects.  
Induced pluripotent stem cells (iPSCs), isolated from patient fibroblasts, 
are currently being developed to model diseases such as AD. It is hoped that this type of 
model system will contribute to the advancement of regenerative therapies to clinical 
stages. For continued studies on the aspects presented in this thesis, model systems such 
as iPSCs-derived neurons and glial cells would constitute unique tools for further 
investigating cellular processes as well as molecular targets for neuroprotective and 
neurotrophic drugs such as (+)-phenserine and α7 nAChR modulators. On a systems 
biology level, the development of biomarkers for in vivo non-invasive assessment of 
neurogenesis and pathological changes is essential for the evaluation of these types of 
interventions longitudinally, at both pre-clinical and potentially clinical levels.  
 
As discussed throughout the thesis, a large number of factors and their interplay are 
important for the development of AD. Despite the occurrence of disease-specific 
pathological changes in the brain, some individuals do not develop AD. The factors 
behind this phenomenon may be many, including genetic, epigenetic and lifestyle 
factors, but I believe that the brain’s ability to use intrinsic mechanisms to stimulate 
neuroprotection and brain repair to sustain cognitive functions, could be part of the 
answer. 
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